US Pat. No. 10,968,318

HETEROCHAIN POLYMER COMPOSITION

Saint-Gobain Performance ...

1. A polymerizable composition comprising:one or more organosiloxanes or organosilanes, the one or more organosiloxanes or organosilanes comprising one or more of
one or more first organosiloxanes or organosilanes including at least one organosiloxane comprising about two or more siloxane repeat units, each comprising a plurality of silicon hydride functional groups, present in an amount within the range of about 0.05 wt % to about 99.95 wt %;
one or more second organosiloxanes or organosilane, each comprising a plurality of reactive heterocycloalkyl functional groups, present in an amount within the range of about 0.05 wt % to about 99.95 wt %; and
one or more third organosiloxanes or organosilanes, each comprising at least about one silicon hydride functional group and at least about one reactive heterocycloalkyl functional group, present in an amount within the range of about 0.05 wt % to about 99.95 wt %;
provided that the composition includes at least one of
the one or more first organosiloxanes or organosilanes, and the one or more third organosiloxanes or organosilanes;
one or more reactive organic compounds, each comprising at least about one reactive heterocycloalkyl functional group, present in an amount within the range of about 0.05 wt % to about 99.95 wt %; and
an effective amount of a borane catalyst,
wherein the ratio of reactive heterocycloalkyl functional groups to reactive silicon hydride functional groups in the composition is in the range of 1:5 to 5:1.
US Pat. No. 10,967,037

PROCESS OF PREPARING VITAMIN E CONCENTRATE

PALM NUTRACEUTICALS SDN. ...

1. A process for modifying the composition of Vitamin E in tocotrienol-rich fraction (TRF) characterized by reducing or removing ?-tocopherol content from a TRF feed material and/or enhancing the content of ?- and ?-tocotrienol in Vitamin E concentrate by a process of solvent extraction and fractionation of TRF feed material, wherein the process of solvent extraction and fractionation for reducing or removing ?-tocopherol and enhancing the content of ?-and ?-tocotrienol in vitamin E concentrate comprises subjecting the TRF feed material to a process comprising the steps of:a. dissolving the TRF feed material in an alcohol to produce a first tocotrienol-rich fraction (TRF1) solution;
b. removing alcohol-insoluble components from the TRF1 solution;
c. adding water to the TRF1 solution to separate a tocotrienol-rich fraction 2 (TRF2) from a saturated tocotrienol-rich fraction 3 (TRF3) solution;
d. saturating the TRF3 solution in aqueous alcohol with a hydrocarbon solvent to produce a TRF3a solution;
e. extracting the TRF3a solution with addition of an additional aliquot of hydrocarbon solvent to obtain a tocotrienol-rich fraction 4 (TRF4) solution in hydrocarbon solvent and a tocotrienol-rich fraction 5 (TRF5) solution;
f. separating the TRF4 solution from the TRF5 solution obtained in step (e);
g. obtaining TRF4 by way of distillation of the TRF4 solution obtained in step (f);
h. partially removing aqueous alcohol from the TRF5 solution obtained in step (f) above by further distillation to obtain a saturated tocotrienol-rich fraction 6 (TRF6) solution and tocotrienol-rich fraction 7 (TRF7);
i. adding hydrocarbon solvent to the saturated TRF6 solution obtained in step (h) above to obtain a tocotrienol-rich fraction 8 (TRF8) and highly polar monoacylglycerol raffinate; and
j. removing solvent residue in TRF7 and TRF8 by distillation.
US Pat. No. 10,968,319

SILICONE HYDROGEL CONTACT LENSES

Alcon Inc., Fribourg (CH...

1. A contact lens precursor, comprising a silicone hydrogel bulk material which comprises:(1) from about 20% to about 79% by weight of first repeating units of at least one silicone-containing polymerizable component, wherein said at least one silicone-containing polymerizable component comprises at least one silicone-containing vinylic monomer, at least one silicone-containing vinylic crosslinker, or a combination thereof;
(2) from 20% to about 79% by weight of second repeating units of at least one hydrophilic vinylic monomer;
(3) from about 1% to about 15% by weight of third repeating units of at least one N-Boc-containing vinylic monomer;
(4) from 0 to about 2.5% by weight of fourth repeat units of at least one non-silicone vinylic crosslinker;
(5) from 0 to about 25% by weight of fifth repeating units of at least one blending vinylic monomer; and
(6) from about 0.1 to about 2.5% by weight of sixth repeating units of at least one UV-absorbing vinylic monomer which comprises 2-[2?-hydroxy-5?-(2-methacryloxyethyl)phenyl)]-2H-benzotriazole and at least one UV/HEVL-absorbing vinylic monomer selected from the group consisting of 2-{2?-Hydroxy-3?-tert-butyl-5?-[3?-methacryloyloxypropoxy]-phenyl}-2H-benzotriazole, 2-{2?-Hydroxy-3?-tert-butyl-5?-[3?-methacryloyloxypropoxy]phenyl}-5-methoxy-2H-benzotriazole, 2-{2?-Hydroxy-3?-tert-butyl-5?-[3?-methacryloyloxypropoxy]-phenyl}-5-chloro-2H-benzotriazole, 2-[2?-Hydroxy-3?-tert-butyl-5?-(3?-acryloyloxypropoxy)-phenyl]-5-trifluoromethyl-2H-benzotriazole, and combinations thereof;
wherein the sum of the amounts of repeating units (a) to (c) present in the silicone hydrogel bulk material is at least 70% by weight.
US Pat. No. 10,967,038

USE OF CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY FOR THE TREATMENT OF CHRONIC OR NON-CHRONIC INFLAMMATORY EYE DISEASES

Xigen Inflammation Ltd., ...

1. A method for treating a chronic or non-chronic inflammatory eye disease in a subject in need thereof, the method comprising administering a JNK inhibitor (poly-) peptide comprising less than 150 amino acids in length to the subject, wherein the chronic or non-chronic inflammatory eye disease is selected from the group consisting of posterior uveitis, an inflammatory eye disease of the blephera, an inflammatory eye disease of the conjunctiva, an an inflammatory eye disease of the sclera, an inflammatory eye disease of the vitreous body, and an inflammatory eye disease of the orbital bone.
US Pat. No. 10,967,294

ENRICHED ROOT POWDER PRODUCTS AND METHODS OF PRODUCING THEREOF

ThermoLife International,...

1. A method of increasing nitrate content in a dried beetroot product, the method comprising:mixing the dried beetroot product with an extraction mixture comprising an alcohol and an acid, wherein the alcohol is a low molecular weight alcohol that is liquid at room temperature;
steeping the mixture of the dried beetroot product and the extraction mixture to produce a steeped mixture;
filtering the steeped mixture to produce a filtered product; and
drying the filtered product to produce a dried filtered product, wherein the nitrate content of the dried filtered product is greater than the nitrate content of the dried beetroot product.
US Pat. No. 10,967,039

PROCESS FOR PREPARING STEALTH NANOPARTICLES

SINTEF TTO AS, Trondheim...

1. A process for the preparation of nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion, wherein said miniemulsion comprises:(i) at least one alkyl cyanoacrylate monomer;
(ii) at least two different polyalkylene glycols independently selected from the group consisting of polyethylene glycols (PEG), polypropylene glycols (PPG), and copolymers thereof; and
(iii) optionally one or more active agents,
wherein at least one of said polyalkylene glycols initiates the single step anionic polymerisation reaction.
US Pat. No. 10,967,040

METHODS OF TREATING PRADER-WILLI SYNDROME WITH CARBETOCIN

Levo Therapeutics, Inc., ...

1. A method of treating Präder-Willi syndrome comprising administering intranasally to a subject having Präder-Willi syndrome three doses per day of 3.2 mg/dose carbetocin, for at least one month, wherein the administration results in a decrease in hyperphagia compared to placebo.
US Pat. No. 10,967,552

VOID-CONTAINING POLYESTER FILM AND METHOD FOR PRODUCING SAME

TOYOBO CO., LTD., Osaka ...

1. A void-containing polyester film comprising:an internal void-containing layer (layer A),
wherein the layer A contains a polyester matrix resin and a polypropylene dispersed resin,
wherein the layer A comprises 3 to 25% by mass of the polypropylene dispersed resin, based on a total amount of resin in the layer A, the polypropylene dispersed resin having a dispersed particle diameter of from 7.5 to 12.2 ?m,
wherein 26 to 50 voids having an area of 10 to 50 ?m2 are present per 10000 ?m2 when observing a vertical cross section of the film,
wherein the layer A does not contain a compatibilizer,
wherein the layer A satisfies the following requirements (1) to (3), and
an apparent density of the film is in a range of 0.8 to 1.2 g/cm3,(1) a melt viscosity (?1) of the polyester resin at a melting temperature of 280° C. and a shear rate of 121.6 sec?1 is 90 to 400 Pa·s,(2) a melt viscosity (?2) of the polypropylene resin at a melting temperature of 280° C. and a shear rate of 121.6 sec?1 is 300 to 850 Pa·s, and(3) a ratio ?2/(?1) of the melt viscosity (?2) of the polypropylene resin to the melt viscosity (?1) of the polyester resin at a melting temperature of 280° C. and a shear rate of 121.6 sec?1 is 1.6 to 4.2.
US Pat. No. 10,968,322

METHOD FOR IMPROVED PRODUCTION OF FERMENTABLE SUGARS FROM LIGNOCELLULOSIC BIOMASS USING ADDITIVE AND ENZYME

INDIAN OIL CORPORATION LI...

1. A method for production of fermentable sugars from lignocellulosic biomass, comprising:a) feeding a grounded lignocellulosic biomass feedstock into a pretreatment reactor system for dilute acid impregnation at room temperature or at a temperature ranging from 50-100° C. for a period 5-60 minutes to render it acid-soaked;
b) removing 40% 70% acid from said acid-soaked biomass by pressing in a hydraulic press to form a pressed biomass;
c) feeding said pressed biomass to a plug mill using feed hopper with feed rate of 8-12 kg/hour for conversion into solid plug(s) of the biomass;
d) treating said solid plug(s) with dilute acid in an amount of 0.02 to 3% w/w of the biomass having pH 1-3 at 120-200° C. for a residence time in the range of 8-12 minutes for conversion into biomass slurry;
e) centrifuging said biomass slurry for separating solids and liquids, followed by washing solids to a pH of 7.0; and
f) hydrolyzing said solids with an additive and enzyme for 40-50 hours in an incubator shaker at 45-55° C. having speed of 180-220 rpm to obtain fermentable sugars.
US Pat. No. 10,967,811

SOUND INSULATION COMPOSITION AND SOUND INSULATION SHEET FOR VEHICLE

BYD COMPANY LIMITED, She...

1. A sound insulation composition, comprising:50 to 300 parts by weight of EVA,
10 to 300 parts by weight of mica powders,
10 to 300 parts by weight of dolomite,
10 to 50 parts by weight of a thermoplastic resin,
10 to 100 parts by weight of a toughening agent,
3 to 60 parts by weight of a compatibilizer,
30 to 300 parts by weight of a fire retardant,
10 to 80 parts by weight of a plasticizer, and
100 to 500 parts by weight of barium sulfate.
US Pat. No. 10,967,043

AGONISTS OF GUANYLATE CYCLASE AND THEIR USES

Bausch Health Ireland Lim...

1. A method of colonic cleansing, the method comprising administering to a subject in need thereof an effective amount of a composition comprising a phosphate salt laxative and a composition comprising an effective amount of a guanylate cyclase receptor agonist (GCRA) peptide consisting essentially of the sequence of SEQ ID NO: 9.
US Pat. No. 10,967,044

LIPOPEPTIDES FOR USE IN TREATING LIVER DISEASES AND CARDIOVASCULAR DISEASES

1. A method for the treatment of a cardiovascular disease (CVD) in a patient comprising administering a therapeutically effective amount of a lipopeptide to the patient, wherein the lipopeptide comprises a peptide of the general formulaX?P?Y?R0
wherein
P is the amino acid sequence NPLGFXaaP (SEQ. ID NO: 1),
wherein Xaa is an arbitrary amino acid;
X is an amino acid sequence having a length of m amino acids,
wherein m is at least 4;
Y is an amino sequence having a length of n amino acids,
wherein n is 0 or at least 1;
and wherein m+n>11;
R is a C-terminal modification of said hydrophobic modified peptide, and
o is 0 or at least 1.
US Pat. No. 10,967,045

MULTICOMPONENT MENINGOCOCCAL VACCINE

Secretary of State for He...

1. A composition comprising:(i) isolated N. meningitidis outer membrane vesicles;
(ii) at least one isolated N. meningitidis antigenic protein, wherein said at least one isolated N. meningitidis antigenic protein
(a) has been extracted from an outer membrane of an N. meningitidis bacterium; or
(b) is a recombinant N. meningitidis antigenic protein; and
(iii) alum in an amount effective as an adjuvant;
wherein said isolated N. meningitidis outer membrane vesicles are from a first strain of N. meningitidis and said at least one isolated N. meningitidis antigenic protein is from a second strain of N. meningitidis different from the first,
said at least one isolated N. meningitidis antigenic protein is not transferrin binding protein A (TbpA) nor transferrin binding protein B (TbpB), and
the N. meningitidis outer membrane vesicles are isolated by desoxycholate treatment.
US Pat. No. 10,968,327

METHODS FOR FORMULATING POLYISOCYANURATE FOAM-FORMING COMPOSITIONS, RELATED POLYISOCYANURATE FOAM-FORMING COMPOSITIONS, AND FOAMS PRODUCED THEREBY

Covestro LLC, Pittsburgh...

1. A method for formulating a polyisocyanurate foam-forming composition, comprising:a) an organic polyisocyanate,
b) a polyol composition comprising at least one polyester polyol with a nominal hydroxyl functionality of at least 2.0,
c) a blowing agent composition present in an amount sufficient to produce foam having a density of less than 1.85 lb/ft3 and comprising:
(1) a hydrocarbon having an atmospheric pressure boiling point of at least 68° F. (20° C.), and
(2) water,
d) a trimerization catalyst,
e) a flame retardant, and
f) a non-reactive silicone surface-active agent,
the method comprising:
(A) evaluating a measured Relative Hydrocarbon Solubility and, optionally, evaluating a measured a Surfactant Water Solubility, a Surfactant Turbidity, or evaluating both the Surfactant Water Solubility and the Surfactant Turbidity; and
(B) formulating the polyisocyanurate foam-forming composition with a non-reactive silicone surface-active agent that either:
(i) has a Relative Hydrocarbon Solubility of at least 1.20; or
(ii) has a Surfactant Water Solubility of less than 2%, a Surfactant Turbidity greater than 100, and a Relative Hydrocarbon Solubility of at least 1.05 and less than 1.20.
US Pat. No. 10,967,046

ALBUMIN-PROAEROLYSIN PRODRUGS

The Johns Hopkins Univers...

1. A prodrug composition comprising:a. a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and
b. human serum albumin (HSA) fused to the N-terminus of the PSA-activated PA.
US Pat. No. 10,967,047

MITOCHONDRIAL ANTIVIRAL-SIGNALING (MAVS) POLYPEPTIDES AND DETECTION AND USE THEREOF

University of Vermont and...

1. A method of selecting an autoimmune disease treatment for a subject, comprising:(a) identifying a subject at risk for a type 1 interferon (IFN) signature autoimmune disease;
(b) obtaining a serum sample from the subject;
(c) contacting the serum sample with a mitochondrial antiviral signaling (MAVS)-binding agent under suitable conditions for the MAVS-binding agent to form a bound complex comprising the MAVS-binding agent and an oligomerized MAVS polypeptide complex, wherein the MAVS-binding agent is a MAVS-binding antibody or antigen-binding fragment thereof;
(d) determining a characteristic of the bound complex, wherein the characteristic of the bound complex comprises one or more of (i) the presence or absence of an oligomerized MAVS polypeptide complex, and (ii) an amount or level of an oligomerized MAVS polypeptide complex in the serum sample, wherein one or more of: the presence of oligomerized MAVS polypeptide complex in the sample and a higher amount or level of the oligomerized MAVS polypeptide complex in the sample compared to a control amount or level, identifies the subject as at risk of the type 1 IFN signature autoimmune disease;
(e) selecting a treatment for the type 1 IFN signature autoimmune disease based at least in part on the subject's identified risk; and
(f) administering the selected treatment for the type 1 IFN signature autoimmune disease to the subject.
US Pat. No. 10,968,329

METHOD OF RECOVERING DECOMPOSITION PRODUCT OF THERMOSETTING RESIN CURED PRODUCT AND METHOD OF PRODUCING RECYCLED MATERIAL

SHOWA DENKO MATERIALS CO....

1. A method of recovering a decomposition product of a thermosetting resin cured product, the method comprising:a step of contacting an object to be treated, that contains a thermosetting resin cured product comprising an epoxy resin cured product, with a treatment liquid containing an alkali metal compound and an alcohol solvent, to decompose and dissolve the thermosetting resin cured product;
a step of mixing the treatment liquid, in which a decomposition product of the thermosetting resin cured product is dissolved, and an acidic aqueous solution to separate a resulting mixture into an aqueous layer and an organic layer containing the decomposition product; and
a step of recovering the organic layer,
wherein the acidic aqueous solution comprises at least one acidic substance selected from the group consisting of hydrochloric acid, a phosphoric acid, an acidic salt of a phosphoric acid, ferric chloride, and aluminum sulfate.
US Pat. No. 10,967,048

USE OF PRG4 AS AN ANTI-INFLAMMATORY AGENT

Lubris LLC, Framingham, ...

1. A method of treating an inflammatory bowel disease in a patient suffering from the inflammatory bowel disease, comprising administering proteoglycan 4 (PRG4) comprising the amino acid sequence of residues 25-1404 of SEQ ID NO:1 to the gastrointestinal tract of the patient in need thereof by oral administration, rectal administration, administration to the colon, administration to the small intestine, administration to the stomach, or through a combination thereof.
US Pat. No. 10,968,330

PARTICULATE NUCLEATING AGENT AND METHOD FOR MANUFACTURING THE SAME

GCH Technology Co., Ltd.,...

1. A particulate nucleating agent comprising active ingredients in a weight content of no less than 90 weight % and having an average radial crushing strength of 1.64-25.0 N/cm, wherein the particulate nucleating agent comprises large size nucleating agent particles having average volume greater than 200 mm3, middle size nucleating agent particles having average volume of 0.5-200 mm3 and powdery nucleating agent particles having average volume less than 0.5 mm3, and a weight content of the middle size nucleating agent particles in the total particulate nucleating agent is no less than 82.3 weight %.
US Pat. No. 10,967,049

FUSION PROTEINS CONTAINING INSULIN-LIKE GROWTH FACTOR-1 AND EPIDERMAL GROWTH FACTOR AND VARIANTS THEREOF AND USES THEREOF

IGF Oncology, LLC, Pine ...

1. A method of treating cancer in a mammal comprising:administering to the mammal a compound comprising an anti-cancer chemotherapeutic agent covalently attached to a fusion polypeptide comprising:
either SEQ ID NO:1 or residues 2-18 of SEQ ID NO:1; fused directly to the N-terminus of a cytokine;
wherein the cytokine is a ligand to ErbB-1 and ErbB-1 is overexpressed in the cancer cells or wherein the cytokine is a ligand to IGF-1R and IGF-1R is overexpressed in the cancer cells; thereby inhibiting the growth of the cancer cells.
US Pat. No. 10,968,331

SHEA BUTTER-CONTAINING RUBBER COMPOSITIONS AND RELATED METHODS

Bridgestone Americas Tire...

1. A tread component of a tire, the tread component being made of a rubber composition, the rubber composition comprising a conjugated diene polymer and about 1 to about 50 phr of shea butter, the shea butter having a fatty acid profile comprising at least 30 weight percent of stearic acid based on the weight of the fatty acid present in the shea butter.
US Pat. No. 10,967,050

THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE

Rani Therapeutics, LLC, ...

1. A therapeutic preparation comprising pramlintide for the treatment of a blood glucose regulation disorder, the preparation shaped as a tissue penetrating member having a dart-like structure, the preparation configured to be contained in an swallowable capsule having a tubular shape with curved ends and to be released from the swallowable capsule to penetrate and be inserted into a gastro-intestinal (GI) lumen wall of a patient by the application of force upon the preparation, wherein upon insertion into the GI lumen wall, the preparation releases the pramlintide into the blood stream from the GI lumen wall to treat the blood glucose regulation disorder.
US Pat. No. 10,967,051

METHODS AND COMPOSITIONS FOR TREATING NAFLD, HEPATIC STEATOSIS, AND SEQUELAE THEREOF

Oramed Ltd., Jerusalem (...

1. A method for inhibiting the development of or treating nonalcoholic fatty liver disease (NAFLD) in a human subject in need thereof, said method comprising the step of orally administering to the subject a water-free pharmaceutical composition comprising a therapeutic protein that inhibits the development of or treats the subject's NAFLD, a protease inhibitor, and a chelator of divalent cations,thereby inhibiting the development of or treating the subject's NAFLD, wherein the therapeutic protein consists of insulin.
US Pat. No. 10,967,052

TREATMENT OF DYSLEXIA USING BOTULINUM TOXIN

PENLAND FOUNDATION, Beau...

1. A method for treating dyslexia or reading developmental disorder (RDD) in a patient in need thereof, comprising administering botulinum toxin to the patient, thereby treating dyslexia or reading developmental disorder (RDD),wherein administering for an adult comprises, by subcutaneous or intradermal injection, 2-4 units to and/or around the vicinity of a trigeminal nerve, 2-4 units to and/or around the vicinity of a cervical nerve, lateral to the patient's spine, 2-4 units to and/or around the vicinity of a thoracic nerve, lateral to the patient's spine, 2-4 units to and/or around the vicinity of a lumbar nerve, lateral to the patient's spine, and/or 2-4 units to and/or around the vicinity of a sacral nerve, lateral to the patient's spine.
US Pat. No. 10,967,053

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A peptide consisting of the amino acid sequence of FLTAINYLL (SEQ ID NO: 72) in the form of a pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.
US Pat. No. 10,968,335

RUBBER CROSSLINKED PRODUCT

ZEON CORPORATION, Tokyo ...

1. A cross-linked rubber obtained by crosslinking a rubber composition comprising (i) a rubber ingredient containing a conjugated diene rubber; and (ii) an inorganic filler, wherein:the cross-linked rubber has a ratio L(i)/L(m) of 0.85 or less, where:
L(i) is a loss tangent value of an interface component of the cross-linked rubber ingredient, the interface component being an interface portion of the cross-linked rubber ingredient forming an interface with the inorganic filler,
L(m) is a loss tangent value of a non-interface component of the cross-linked rubber ingredient, the non-interface component being a portion of the cross-linked rubber ingredient other than the interface portion, and
L(i) and L(m) are measured using an atomic force microscope in a state in which sinusoidal vibrations of 5 kHz are applied to the cross-linked rubber,
the weight average molecular weight (Mw) of the conjugated diene rubber is in the range of from 510,000 to 2,000,000.
US Pat. No. 10,967,054

METHODS OF CANCER TREATMENT USING ACTIVATED T CELLS

SYZ CELL THERAPY CO., Gu...

1. A method of treating a cancer in an individual, comprising administering to the individual an effective amount of activated T cells, wherein the activated T cells are prepared by co-culturing a population of T cells with a population of dendritic cells loaded with a plurality of tumor antigen peptides having pre-determined amino acid sequences, wherein the plurality of tumor antigen peptides comprises at least one epitope having an amino acid sequence selected from the group consisting of SEQ ID NOs: 36-38 and 41-44, and wherein the population of dendritic cells loaded with the plurality of tumor antigen peptides is prepared by contacting the population of dendritic cells with the plurality of tumor antigen peptides.
US Pat. No. 10,968,336

FLAME RETARDANT COMPOSITION AND FLAME RETARDANT SYNTHETIC RESIN COMPOSITION

ADEKA CORPORATION, Tokyo...

1. A flame retardant synthetic resin composition comprising (i) a polyolefin resin and (ii) a flame retardant composition, wherein the flame retardant composition comprises (A) 40 to 50 parts by mass of melamine pyrophosphate, (B) 50 to 60 parts by mass of piperazine pyrophosphate, the sum of the components (A) and (B) being 100 parts by mass, and (C) 5 to 15 parts by mass of ?-cyclodextrin.
US Pat. No. 10,967,055

VACCINE FOR IMMUNIZATION AGAINST Q-FEVER

1. A vaccine composition comprising a bacterial extract purified from Coxiella burnetti cells, wherein the bacterial extract comprises a protein antigen that is capable of producing an immune response in a host, when said vaccine composition is administered at a dose that is sufficient for preventing onset of Q fever in said host, and wherein the protein antigen is SolWCVII.
US Pat. No. 10,967,056

PROTEINS AND IMMUNIZING COMPOSITIONS CONTAINING PASTEURELLA PROTEINS AND METHODS OF USE

Epitopix, LLC, Willmar, ...

1. A composition comprising: an isolated protein having at least 95% similarity to amino acids 25-968 of SEQ ID NO:2, an isolated protein having at least 95% similarity to amino acids 27-790 of SEQ ID NO:4, an isolated protein having at least 80% similarity to amino acids 23-727 of SEQ ID NO:6, an isolated protein having at least 95% similarity to amino acids 25-964 of SEQ ID NO:8, an isolated protein having at least 95% similarity to amino acids 26-848 of SEQ ID NO: 10, an isolated protein having at least 95% similarity to amino acids 27-784 of SEQ ID NO: 12, and an isolated protein having at least 95% similarity to amino acids 25-742 of SEQ ID NO: 14, and an adjuvant.
US Pat. No. 10,968,338

FLAME RETARDANT POLYMERIC COMPOSITION

Dow Global Technologies L...

1. A composition comprising:a silanol functionalized polyolefin;
an anhydride-free brominated flame retardant;
antimony trioxide; and
the composition has an antimony (Sb) to bromine (Br) molar ratio (Sb:Br molar ratio) from 0.37 to 1.05.
US Pat. No. 10,967,057

ZIKA VIRAL ANTIGEN CONSTRUCTS

GLAXOSMITHKLINE BIOLOGICA...

1. A method of inducing an immune response against a Zika virus infection in a subject in need thereof, which comprises administering to said subject a composition comprising an immunologically effective amount of a self-replicating RNA molecule comprising a construct encoding a polypeptide at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:26; SEQ ID NO:31; SEQ ID NO:36; SEQ ID NO:41; SEQ ID NO:46; SEQ ID NO:52; and SEQ ID NO:58.
US Pat. No. 10,968,339

ANTIOXIDANT-CONTAINING FOAMABLE RESIN PARTICLES, METHOD FOR PRODUCING SAME, FOAMABLE PARTICLES, AND FOAM-MOLDED ARTICLE

SEKISUI PLASTICS CO., LTD...

1. A method for producing antioxidant-containing expandable resin particles, the method comprising:impregnating composite resin particles with an antioxidant, a blowing agent, and optionally a flame retardant, to obtain said antioxidant-containing expandable resin particles comprising:
composite resin particles, the antioxidant, the blowing agent, and optionally a flame retardant;
said antioxidant being contained in the composite resin particles in an amount of 150 to 1500 ppm;
wherein said composite resin particles contain a polystyrene-based resin and a polypropylene-based resin, said polystyrene-based resin is contained in the composite resin particles in an amount of 100 to 400 parts by mass relative to 100 parts by mass of polypropylene-based resin, and wherein the polypropylene-based resin is abundantly present on the surface of the composite resin particles and poorly present at the center of the particles.
US Pat. No. 10,967,058

FOOT-AND-MOUTH DISEASE VACCINE

Zoetis Services LLC, Par...

1. An immunogenic composition comprising an antigen component and an adjuvant component, whereina) the adjuvant component comprises an emulsion containing oil, an immunostimulatory oligonucleotide, and diethylaminoethyl (DEAE) Dextran and
b) the antigen component comprises 0.5-10 ?g or 6-20 ?g of FMD (Foot-and-Mouth Disease) virus composition per dose.
US Pat. No. 10,967,059

TOOTHPASTE FOR DELIVERY OF ALLERGENS TO ORAL MUCOSA

Allovate, LLC, New York,...

1. A method of formulating a toothpaste suitable for oral mucosal therapy, the method comprising:providing a first volume of solution comprising an allergen or allergen extract and a concentration of sugar alcohol;
formulating a second volume of pro-toothpaste comprising a concentration of vehicle and a concentration of thickener, the vehicle comprising a sugar alcohol corresponding to the sugar alcohol of the first volume in identity and in a concentration substantially corresponding to the concentration of sugar alcohol of the first volume, the first and second volumes being combinable in a ratio such that a concentration of sugar alcohol in the combined volume is between about 40% and 55% by volume, and mixing the first volume and second volume in the ratio.
US Pat. No. 10,968,341

LIQUID COMPOSITION COMPRISING A MULTISTAGE POLYMER, ITS METHOD OF PREPARATION AND ITS USE

Arkema France, Colombes ...

1. A process for manufacturing a liquid composition comprising the steps of:a) preparing a composition comprising a (meth) acrylic polymer (P1) having a mass average molecular weight Mw of less than 100,000 g/mol and a multi stage polymer, said multistage polymer being in the form of core shell particles having a multilayer structure comprising at least one layer (A) comprising a polymer (A1) having a glass transition temperature below 0° C. and another layer (B) comprising a polymer (B1) having a glass transition temperature over 30° C., said layer (A) being made in the first stage of a multistage process and forming the core for the polymer particle having the multilayer structure, and
b) mixing the composition of previous step with a monomer (M1),
wherein the multistage polymer to monomer (M1) ratio in the liquid composition is between 1/99 and 25/75, such that the multistage polymer is homogenously dispersed in said liquid composition.
US Pat. No. 10,968,342

PROCESS FOR PREPARING AN AQUEOUS DISPERSION OF MULTISTAGE POLYMER PARTICLES

Rohm and Haas Company, C...

1. A process for preparing an aqueous dispersion of neutralized multistage polymer particles comprising the steps of:1) contacting under emulsion polymerization conditions a) an aqueous dispersion of first polymer particles comprising from 25 to 65 weight percent structural units of a carboxylic acid monomer, and from 40 to 75 weight percent structural units of a nonionic monomer with b) first monomers comprising, based on the weight of the first monomers, i) from 80 to 99.5 weight percent styrene or methyl methacrylate or a combination thereof, and ii) from 0.5 to 20 weight percent of a carboxylic acid monomer; to form an aqueous dispersion of 2-stage polymer particles; then
2) contacting under emulsion polymerization conditions the aqueous dispersion of the 2-stage polymer particles with second monomers comprising, based on the weight of the second monomers a) from 1 to 60 weight percent methyl methacrylate, b) from 35 to 98.5 weight percent n-butyl acrylate, 2-ethylhexyl acrylate, ethyl acrylate, or n-butyl methacrylate, or a combination thereof; c) from 0.5 to 5 weight percent of a carboxylic acid monomer; and d) less than 20 weight percent styrene, to convert the 2-stage polymer particles to unneutralized 3-stage polymer particles; then
3) neutralizing the unneutralized aqueous dispersion of the 3-stage polymer particles with a base to form an aqueous dispersion of neutralized 3-stage polymer particles having an average particle size in the range of 150 nm to 400 nm;
wherein the weight-to-weight ratio of the first polymer particles to the first and second monomers is in the range of from 1:2 to 1:9; and the weight-to-weight ratio of the first monomers to second monomers is in the range of from 3:2 to 1:8;
wherein the first and second monomers form a shell having a calculated Tg of less than 50° C.
US Pat. No. 10,967,061

METHODS FOR PROTECTING AND TREATING TRAUMATIC BRAIN INJURY, CONCUSSION AND BRAIN INFLAMMATION WITH INTRANASAL INSULIN

The Henry M. Jackson Foun...

1. A method for treating traumatic brain injury (TBI) in a patient, wherein the patient's risk of developing Alzheimer's disease is increased by the TBI, comprising:administering a therapeutic agent consisting of at least an effective amount of insulin to the upper third of the nasal cavity of the patient, and thereby enabling at least an effective amount of insulin to directly access the patient's central nervous system by bypassing the blood-brain barrier; and
treating the patient's TBI, and protecting against the patient developing Alzheimer's disease as a result of the TBI by protecting the patient's brain from inflammation and reducing inflammation in the patient's brain by increasing the expression of anti-inflammatory M2 microglia cells in the patient's brain.
US Pat. No. 10,968,343

FORMALDEHYDE-FREE CURABLE FORMULATION

Rohm And Haas Company, C...

1. A curable aqueous formulation comprisinga) an emulsion polymer with 5 to 20 weight percent acid monomers;
b) an oxazoline-containing polymer; and
c) an aqueous acrylic polymer dispersion with 40 to 100 weight percent acid monomers and having a weight average molecular weight in the range of from 2000 to 500000.
US Pat. No. 10,967,062

FUNCTIONALIZED NANOPARTICLES AND METHODS OF USE THEREOF

Regents of the University...

1. A nanoparticle comprising a polymer and one or more units of formula (I):A-B-C-D  (I)
wherein A is poly-lactic acid or poly-(lactic-co-glycolic acid); B is poly-(ethylene glycol); C is a linking group and D is one or more moieties independently selected from tissue plasminogen activator (tPA) and recombinant tissue plasminogen activator (r-tPA), wherein the r-tPA is alteplase or reteplase.
US Pat. No. 10,968,344

POLYESTER COMPOSITION SUITABLE FOR ULTRASONIC WELDING AND PREPARATION METHOD THEREOF

SHANGHAI KUMHOSUNNY PLAST...

1. A polyester composition suitable for ultrasonic welding, wherein the composition comprises the following components in parts by weight:30˜50 parts of poly(1,4-cyclohexylene dimethylene terephthalate),
40˜60 parts of ABS,
5˜10 parts of a melt enhancer,
0.1˜1 parts of an antioxidant, and
0.1˜1 parts of a lubricant.
US Pat. No. 10,967,063

SURFACTANT-FREE, WATER-FREE FORMABLE COMPOSITION AND BREAKABLE FOAMS AND THEIR USES

Vyne Therapeutics Inc., ...

1. A method of treating acne vulgaris or rosacea, comprising administering a waterless foam composition free of surfactant and polymeric agent comprisinga tetracycline antibiotic and a foamable carrier,
the foamable carrier comprising:
a) about 50% to about 90% by weight of the foamable carrier of a liquid oil and about 10% to about 50% by weight of the foamable carrier of a paraffin wax selected from the group consisting of a paraffin wax having a melting point of 58-62° C., a paraffin wax having a melting point of 51-53° C. and a mixture thereof, wherein the total weight of the liquid oil and wax together is between about 85% and about 100% by weight of the foamable carrier; or
b) about 40% by weight of the foamable carrier of a liquid oil and about 60% by weight of the foamable carrier of a paraffin wax having a melting point of 42-44 c?C; and
a liquefied or compressed gas propellant; and
wherein the ratio of the foamable carrier to the propellant is from about 100:4 to about 100:25; and
wherein the composition is substantially free of a foam adjuvant.
US Pat. No. 10,968,345

POLYESTER COMPOSITION

NOVAMONT S.P.A., Novara ...

1. A polymeric composition which comprises:A. from 10-70% by weight of at least one aromatic polyester (AP) comprising
a1) units derived from a diol component selected from 1,4-butanediol and 1,2-ethanediol; and
a2) units derived from an acid component, said units derived from said acid component comprising from 70 to 100 mol % of repeating units deriving from at least one heterocyclic polyfunctional aromatic acid of renewable origin selected from the group consisting of 2,5-furandicarboxylic acid and 5-hydroxymethyl-2-furancarboxylic acid,
and said at least one aromatic polyester (AP) having a molecular weight Mn from 40,000 to 150,000 and a polydispersity index KAI, from 1.5 to 5; and
B. from 90-30% by weight of at least a biodegradable aliphatic-aromatic polyester (AAPE) comprising:
b1) units deriving from at least one dicarboxylic aromatic compound selected from the group consisting of (C) and (D); wherein said (C) is at least one of an aromatic acid of the phthalic acid type and ester thereof; and said (D) is at least one of 2,5-furandicarboxylic acid and ester thereof; and aliphatic units deriving from the group consisting of adipic acid, succinic acid, suberic acid, azelaic acid, sebacic acid, dodecandioic acid, brassylic acid, and mixtures thereof; and wherein said (C) comprises from 40 to 75 mol % of units deriving from said phthalic acid type and ester thereof with respect to the total molar diacid content; and said (D) comprises from 30 to 70 mol % of units deriving from said 2,5-furandicarboxylic acid and ester thereof with respect to the total molar diacid content;
b2) units derived from 1,4-butanediol; said aliphatic-aromatic polyester (AAPE) having a molecular weight Mn from 40,000 to 150,000 and a polydispersity index Mw/Mn from 1.5 to 5.
US Pat. No. 10,971,423

METAL NANOWIRE BASED THERMAL INTERFACE MATERIALS

CARNEGIE MELLON UNIVERSIT...

1. A thermal interface layer comprising:a seed layer of copper; and
a plurality of nanowires having a copper portion and a tin portion grown on the seed layer, the nanowires having a height;
wherein the plurality of nanowires cover approximately 30% to 75% of the seed layer; and
wherein the plurality of nanowires are vertically-aligned from the seed layer to their height.
US Pat. No. 10,967,064

PREPARATION METHOD FOR A DNA ORIGAMI BASED CARRIER SYSTEM

YEDITEPE UNIVERSITESI, I...

1. A preparation method for a DNA origami based carrier, comprising the following steps:preparing a first DNA origami based carrier, comprising the following steps:
mixing complementary oligonucleotides in a first hybridization buffer to obtain a first hybridization mixture;
incubating the first hybridization mixture in a water bath at 95° C. to obtain a second hybridization mixture;
slowly cooling the second hybridization mixture from 95° C. to room temperature to obtain a first DNA origami based carrier; and
characterizing the first DNA origami based carrier to obtain a molecular weight and a size of the first DNA origami based carrier;
synthesizing a lactose modified oligonucleotide, comprising the following steps:
mixing a lactose, a 5?-aminohexyloligonucleotide and a sodium cyanoborohydride in a borate buffer (pH 8) to obtain a first mixture;
stirring the first mixture at a room temperature for 12 hours to obtain a second mixture; and
centrifuging the second mixture to remove unreacted chemicals to obtain the lactose modified oligonucleotide;
hybridizing the lactose modified oligonucleotide to the first DNA origami based carrier, comprising a step of:
mixing the first DNA origami based carrier and the lactose modified oligonucleotide in a second hybridization buffer at room temperature for 18 hours to obtain a second DNA origami carrier; and
intercalating a doxorubicin into the second DNA origami based carrier, comprising t following steps:
mixing the second DNA origami based carrier and the doxorubicin in a third hybridization buffer to obtain a third mixture;
stirring the third mixture at room temperature for 24 hours to obtain a doxorubicin intercalation mixture; and
centrifuging the doxorubicin intercalation mixture to collect a third DNA origami based carrier, wherein the third DNA origami based carrier is loaded with doxorubicin.
US Pat. No. 10,967,065

COMPOUNDS FOR TREATING BIOFILM INFECTION

BOARD OF REGENTS, THE UNI...

1. A compound comprising amikacin covalently bound to a poly(ethylene glycol) via a —NH—C(O)— bond.
US Pat. No. 10,967,066

STAPLED ACID-SENSITIVE ENDOSOME DISRUPTING ALGINATES

21. A method comprising delivering at least one cation to the cytosol of a prokaryotic or eukaryotic cell, comprising contacting the cell with the agent of claim 1.
US Pat. No. 10,968,349

COMPOSITION AND METHOD FOR REDUCING ALDEHYDE CONTENT IN POLYURETHANE FOAMS

1. A composition comprising:(a) a polyether polyol produced by reacting one or more epoxide compounds with a multifunctional initiator compound selected from the group consisting of multifunctional alcohols and multifunctional amines;
(b) a polyethylenimine compound; and
(c) a sulfite compound.
US Pat. No. 10,968,350

ADHESIVE COMPOSITIONS AND METHODS

Saudi Aramco Technologies...

1. A composition comprising a polyurethane and a block copolymer comprising four or more homopolymer subunits selected from the group consisting of polyolefins and fluoropolymers,wherein:the block copolymer comprises one or more fluoropolymer subunits; and
the polyolefin homopolymer subunits of the block copolymer are selected from the group consisting of polyethylene subunits or C3-C6 ?-polyolefin subunits.
US Pat. No. 10,967,070

CELL PENETRATING CONJUGATES AND METHODS OF USE THEREOF

CITY OF HOPE, Duarte, CA...

1. An antibody covalently attached to one or more phosphorothioate nucleic acids, wherein the one or more phosphorothioate nucleic acids are independently from 10 to 30 residues in length, wherein the antibody binds an intracellular target and wherein the antibody is non-cell penetrating in the absence of said one or more phosphorothioate nucleic acids.
US Pat. No. 10,967,072

SHORT INTERFERING RNA TEMPLATED LIPOPROTEIN PARTICLES (SIRNA-TLP)

Northwestern University, ...

1. An anionic nanostructure aggregate, comprising:an aggregate of cationic lipid-nucleic acid complexes and templated lipoprotein particles (TLP), wherein the TLP comprises an anionic TLP which is a synthetic HDL having an inert core, a lipid shell surrounding the inert core, and an apolipoprotein functionalized to the inert core; and the cationic lipid-nucleic acid complex, comprised of single stranded antisense and sense RNA of an siRNA duplex, each complexed with a cationic lipid, and wherein the aggregate of cationic lipid-nucleic acid complexes and TLPs has a negative ?-potential and forms the anionic nanostructure aggregate.
US Pat. No. 10,967,073

GLUCOCEREBROSIDASE GENE THERAPY FOR PARKINSON'S DISEASE

The McLean Hospital Corpo...

1. A method of treating Parkinson's disease (PD), the method comprising delivering to the central nervous system (CNS) of a subject in need thereof a vector comprising a nucleic acid encoding a glucocerebrosidase protein, wherein the nucleic acid encoding the glucocerebrosidase protein is operably linked to a synapsin promoter, wherein the vector is an AAV2/5 vector, wherein the vector is administered by injection, and wherein the method decreases the size or amount of insoluble ?-synuclein aggregates in one or more brain tissues relative to a control.
US Pat. No. 10,968,355

REVERSIBLE, CHEMICALLY OR ENVIRONMENTALLY RESPONSIVE POLYMERS, AND COATINGS CONTAINING SUCH POLYMERS

HRL Laboratories, LLC, M...

1. A polymer composition comprising:(a) a polymer matrix containing one or more ionic species;
(b) one or more chemical reducing agents capable of causing metal reduction; and
(c) one or more metal ions capable of reversibly changing valence from a first oxidation state to a second oxidation state when in the presence of said chemical reducing agents,
wherein said metal ions, in said first oxidation state, have a first coordination number with said ionic species,
wherein said metal ions, in said second oxidation state, have a second coordination number with said ionic species, and
wherein said first coordination number is greater than said second coordination number.
US Pat. No. 10,967,074

EYE DROP COMPOSITION

ARATANA THERAPEUTICS, INC...

1. A composition comprising:at least 0.1% w/v 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one; and
at least 15% w/v of a cyclodextrin.
US Pat. No. 10,968,356

COALESCENT INK

Hewlett-Packard Developme...

1. A coalescent ink, comprising:a conjugated polymer;
a colorant imparting a visible color to the coalescent ink, wherein the visible color is cyan, magenta, yellow, black, red, blue, green, orange, or violet; and
an ink vehicle comprising a high boiling point co-solvent having a boiling point of 250° C. or greater, the high boiling point co-solvent present in an amount from about 1 wt % to about 4 wt % with respect to the coalescent ink.
US Pat. No. 10,969,380

SIMULTANEOUS DETECTION OF CANNIBALISM AND SENESCENCE AS PROGNOSTIC MARKER FOR CANCER

Institut Gustave Roussy, ...

1. An in vitro method for detecting cannibalism behavior of a cell, comprising:measuring expression level of p53, expression level of a N-terminal isoform of p53 that lacks N-terminal transactivating domain, expression level of p53?, or expression level of p53? in said cell, wherein measuring expression level comprises measuring mRNA level; and
measuring activity of purinergic P2Y2 receptor (P2Y2R) in said cell by determining the phosphorylation of Pyk2.
US Pat. No. 10,967,331

HOLLOW FIBER MEMBRANE

National University of Si...

1. A hollow fiber membrane for vacuum membrane distillation, the hollow fiber membrane having a maximum tensile strength of ?3.5 MPa and a liquid entry pressure (LEP) of ?3.0 bar, wherein the hollow fiber membrane is a single layer hollow fiber membrane comprising a wall with a thickness of ?150 ?m and a cross-section comprising two open cell layers with an array of interconnected pores and a macrovoid layer between the two open cell layers, wherein the hollow fiber membrane is prepared from a dope composition comprising a hydrophobic polymer, an additive and a solvent, the additive comprising a Li+-containing additive.
US Pat. No. 10,967,076

USE OF NON-LABELED SUGARS AND DETECTION BY MRI FOR ASSESSING TISSUE PERFUSION AND METABOLISM

The Johns Hopkins Univers...

1. A method for magnetic resonance (MR) imaging or spectroscopy on a MR scanner, comprising:generating a first recorded MR signal by observing at a first time a tissue area of a subject with a pulse sequence implemented on the MR scanner, said pulse sequence adapted to sensitize said first recorded MR signal to the presence of sugar in said tissue area;
administering sugar to said subject to cause said subject's blood sugar level to become elevated; and
generating a second recorded MR signal by repeating said observing of said tissue area of said subject with said pulse sequence at a second, later time when the subject's blood sugar level is elevated;
detecting a difference between the second recorded MR signal that is sensitized to an elevated level of sugar in said tissue area at the second, later time and the first recorded MR signal that is sensitized to a baseline level of sugar in said tissue area at the first time;
subsequently ascertaining at least one physiological parameter associated with perfusion of blood in said tissue area of said subject under observation based on the detected difference; and
generating a plurality of recorded MR signals prior to, during, and after said administering said sugar to said subject,
wherein said MR scanner is adapted for measuring changes in water MR signals based on a changed water relaxation rate caused by said administered sugar comprising one or more hydroxyl protons that are exchangeable with water molecules in said tissue.
US Pat. No. 10,967,077

IMAGING OF METASTATIC OR RECURRENT CANCER

Blue Earth Diagnostics Li...

1. A method of using anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid ([18F]-FACBC), comprising:a) administering the [18F]-FACBC in a dose of 370 MBq as an intravenous bolus injection into a human subject having a suspected prostate cancer recurrence, wherein the [18F]-FACBC injection is followed by an intravenous flush; and
b) acquiring a positron emission tomography (PET) scan image of the human subject during a PET scan;
wherein the human subject has:
i. consumed no food or drink including water for at least 4 hours prior to the injection, except sips of water for taking medications, and
ii. avoided significant exercise for at least one day prior to the PET scan;
wherein the human subject is positioned in a supine position with arms above the head before the PET scan starts;
wherein the PET scan starts 3 to 5 minutes after the end of the [18F]-FACBC injection;andwherein the PET scan starts from at least the human subject's proximal thigh and proceeds to the base of the human subject's skull for a total scan time of up to 30 minutes.
US Pat. No. 10,969,384

IMMUNOFLUORESCENCE ASSAYS

VECTOR LABORATORIES, INC....

1. A method for lowering/reducing/masking/suppressing tissue autofluorescence in an immunofluorescence assay, said method comprising, before or during conducting said immunofluorescence assay:providing a tissue comprising lung, liver, heart, nervous system, skin, lymph gland, musculoskeletal, spleen, eye, sinus, nasal mucosa, larynx, gastrointestinal tract tissue, reproductive organ, breast, prostate, salivary gland, tonsil, or kidney tissue;
applying a heteropoly acid or salt thereof to said tissue, wherein the heteropoly acid comprises phosphomolybdic acid, phosphotungstic acid, silicomolybdic acid, silicotungstic acid, or a mixture of any two or more thereof or salts thereof;
reducing at least a portion of said heteropoly acid or salt thereof to a reduced form with a reducing agent comprising stannous chloride and/or sodium cyanoborohydride; and
measuring the immunofluorescence of the tissue.
US Pat. No. 10,971,182

MAGNETIC POWDER, MANUFACTURING METHOD OF MAGNETIC POWDER, AND MAGNETIC RECORDING MEDIUM

FUJIFILM Corporation, To...

1. Magnetic powder comprising:at least one epsilon-phase iron oxide-based compound selected from the group consisting of ?-Fe2O3 and a compound represented by Formula (1); and
a surface treatment layer including a silane compound on at least a part of a surface,
wherein the magnetic powder has an average particle diameter of 8 nm to 20 nm, and
a content ratio of carbon atoms of the silane compound included in the surface treatment layer to iron atoms of the at least one epsilon-phase iron oxide-based compound selected from the group consisting of ?-Fe2O3 and the compound represented by Formula (1) is 0.05% to 0.5% in terms of the number of atoms,
?-AaFe2-aO3  (1)
wherein, in Formula (1), A represents at least one metal element other than Fe and a represents a number that satisfies a relationship of 0
US Pat. No. 10,969,386

SAMPLE PLATE SYSTEMS AND METHODS

Dynex Technologies, Inc.,...

1. An Immunoassay sample plate comprising a circular sample well having a circular arrangement of probes, wherein the probes are defined by reagent beads.
US Pat. No. 10,967,338

METHODS OF RELEASING AND ANALYZING CELLULAR COMPONENTS

STOKES BIO LTD., Limeric...

1. A method comprising:controlling fluid flow through one or more channels to generate aqueous droplets wrapped in a carrier fluid that is immiscible with the aqueous droplets, wherein the aqueous droplets comprise a subset of droplets, each droplet of the subset comprising at least one cell, and a lysis reagent;
lysing the at least one cell in each droplet of the subset of droplets to release internal cellular components comprising RNA;
dispensing the RNA of the subset of droplets released from the lysing to a vessel comprising one or more reservoirs; and
while in the vessel, collectively subjecting the RNA of the subset of droplets released from the lysing to a reverse transcription assay to produce cDNA from the RNA.
US Pat. No. 10,969,388

ASSAY AND KIT FOR DETECTION OF ENDOTOXIN

NanoDx Healthcare Pvt. Lt...

1. A membrane based assay method comprising:i) placing a sample suspected of containing an endotoxin on a surface of a membrane having affinity to the endotoxin positioned parallelly to at least one layer of a hydrophilic material and optionally placed in an enclosure for securing therein the at least one layer layer(s) of the hydrophilic material and the membrane having affinity to the endotoxin positioned thereon;
ii) placing at least once a suspension of conjugates of lipopolysaccharide (LPS)-affinity ligand with gold nanoparticles (GNPs) over the same area as the sample placed, wherein the LPS affinity ligand is sushi 3 peptide having SEQ ID NO: 1; and
iii) detecting or quantifying the endotoxin in the sample based on the appearance of a colour signal.
US Pat. No. 10,968,365

FORMULATION TO STOP THE ADHERENCE OF A DYE TO AN EGGSHELL, IMPROVEMENT

1. A method of making a coating for reducing penetration of food dyes on an egg shell surface, the method comprising:a.) admixing, a hydroxide, an edible salt and water wherein the ratio of hydroxide to water is 1:1 to 1:20 to form a solution;
b.) determining the pH level of the solution and optionally adding an acid to lower the pH of the solution;
c.) optionally adding a sugar alcohol to the solution and heating; if;
d.) adding a food grade emulsifier and fatty acid separately or together as;
e.) heating the solution to a temperature between 135-220*F and adding a food grade wax; and
f.) cooling the solution to produce the coating for application onto the egg shell surface.
US Pat. No. 10,969,389

METHOD TO MONITOR AND QUANTIFY INTERPHASE NUCLEAR ENVELOPE RUPTURE EVENTS

INSTITUT CURIE, Paris (F...

1. An in vitro method for screening or identifying a compound capable of increasing or decreasing the intensity and/or frequency of interphase nuclear envelope rupture events in eukaryotic cells comprising:(a) providing a eukaryotic cell expressing a protein fused to a detection entity and having a cytosolic non-nuclear localization in interphase and a non-sequence specific DNA binding activity; and
(b) contacting said cell with a test compound;
(c) measuring the intensity and/or frequency of the detection entity fused to said protein to detect presence of said protein in the nucleus of said cell, thereby measuring the intensity and/or frequency of interphase nuclear envelope rupture events in said cell, respectively; and
(d) comparing the intensity and/or frequency of the presence of the detection entity fused to said protein in the nucleus of said cell with a reference level in the absence of said test compound and determining if said compound increases or decreases the intensity and/or frequency of the presence of the detection entity fused to said protein in the nucleus of said cell, thereby determining if said compound increases or decreases the intensity and/or frequency of said interphase nuclear envelope rupture events,
wherein said protein is a human cGAS that has an E225A mutation or said protein is a human AIM2 that has a F27G mutation.
US Pat. No. 10,969,390

METHOD FOR EVALUATING EFFICACY OF CHEMORADIOTHERAPY AGAINST SQUAMOUS CELL CARCINOMA

NATIONAL CANCER CENTER, ...

1. A method of measuring gene expression in a squamous cell carcinoma, the method comprising:detecting expression levels of at least two genes selected from a SIM2 gene and genes co-expressed with the SIM2 gene in a squamous cell carcinoma specimen isolated from a subject, wherein the genes co-expressed with the SIM2 gene are genes correlated with the expression of the SIM2 gene with a Pearson product-moment correlation coefficient of 0.4 or more.
US Pat. No. 10,969,391

METHODS FOR DIAGNOSING HEMATOLOGICAL CANCERS

CENTRE HOSPITALIER UNIVER...

1. A method for diagnosing and for treating a haematological cancer in a patient comprising:i) obtaining a blood sample or a bone marrow sample from a patient,
ii) detecting the presence of CD45 RARO NK cells in the sample obtained from the patient using of a set of binding partners that are suitable for distinguishing NK cells from other cells and a set of binding partners comprising at least one differential binding partner specific for CD45RA and at least one differential binding partner specific for CD45RO,
iii) concluding that the patient suffers from a haematological cancer when the presence of CD45 RARO NK cells is detected in the sample, and
iv) treating the patient suffering from a haematological cancer with a chemotherapeutic agent, a targeted cancer therapy, an immunotherapeutic agent or a radiotherapeutic agent.
US Pat. No. 10,969,392

METHODS AND SYSTEMS FOR PREDICTING RESPONSE TO IMMUNOTHERAPIES FOR TREATMENT OF CANCER

Vanderbilt University, N...

1. A method of detecting cell membrane expression of an MHC molecule in a subject suspected of having cancer and being in need of immunotherapy, comprising:(a) obtaining a tumor cell sample from the subject;
(b) detecting cell membrane expression of the MHC molecule by contacting the tumor cell sample with an antibody targeting the MHC molecule and detecting binding between the MHC molecule and the antibody;
(c) detecting a cancer specific marker on the tumor cell sample; and
(d) administering a therapeutically effective amount of nivolumab, pembrolizumab, MPDL3280a, or anti-LAG3 to the subject having a tumor cell sample with increased cell membrane expression of the MHC molecule relative to a control as detected in step (b) and positive cancer specific marker staining as detected in step (c);
wherein expression of the MHC molecule is measured using at least one method selected from the group consisting of immunohistochemistry, immunofluorescence, flow cytometry, mass-spectroscopy, or combinations thereof.
US Pat. No. 10,969,393

COMPLEXES BETWEEN ANTI-TNF ANTIBODIES, TRIMERIC TNF PROTEINS AND ORGANIC MOLECULES BINDING THEM

UCB Biopharma SRL, Bruss...

1. A complex comprising (i) an antibody, (ii) a trimeric protein that is a tumor necrosis factor (TNF) superfamily member, and (iii) a compound that is capable of binding to a trimeric protein that is a TNF superfamily member, wherein the antibody comprises(a) a HCDR1/HCDR2/HCDR3 sequence combination selected from SEQ ID NOs: 4/5/6 and SEQ ID NOs: 19/20/21, and a LCDR1/LCDR2/LCDR3 sequence combination selected from SEQ ID NOs: 1/2/3 and SEQ ID NOs: 1/17/18; or
(b) a HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 4/5/6/1/2/3 or SEQ ID NOs: 19/20/21/1/17/18, wherein:
(a) the compound antagonizes the signalling induced by the trimer through the receptor;
(b) the compound increases the thermal transition midpoint (Tm) of the trimeric form of the TNF superfamily member compared to the Tm of the trimeric form of the TNF superfamily member in the absence of the compound;
(c) the compound increases the binding affinity of the TNF superfamily member to the requisite receptor compared to the binding affinity of the TNF superfamily member to its receptor in the absence of the compound; and
(d) the compound has an IC50 value of 500 nM or less.
US Pat. No. 10,969,394

REAGENTS AND METHODS FOR ANALYSIS OF PROTEINS AND METABOLITES TARGETED BY COVALENT PROBES

Dana-Farber Cancer Instit...

1. An analytical method, comprising:i) contacting a test compound with a polypeptide to form a test-compound-polypeptide conjugate;
ii) analyzing the test compound-polypeptide conjugate using a mass spectrometry assay;
III detecting one or more thiolated ions of the test compound or derivative ions thereof, produced in the mass spectrometry assay; and
identifying that the test compound irreversibly bonds to the polypeptide based on the detection of the one or more thiolated ions, or derivative ions thereof, in the mass spectrometry assay; wherein the thiolated ions or derivative ions thereof are fragment ions.
US Pat. No. 10,968,371

MOISTURE CURABLE HOT MELT SEALANT COMPOSITION INCLUDING SILANE FUNCTIONAL POLYURETHANE

H.B. Fuller Company, St....

1. A moisture curable hot melt sealant composition comprising:from 1% by weight to no greater than 12% by weight of a silane-functional polyurethane that is free of isocyanate groups;
at least 10% by weight of a thermoplastic elastomer having a weight average molecular weight of at least 100,000 grams per mole (g/mol) and being derived from 0% by weight to no greater than 30% by weight styrene, based on the weight of the thermoplastic elastomer, the thermoplastic elastomer being selected from the group consisting of butyl rubber, polyisobutylene rubber, ethylene-propylene rubber, ethylene-propylene diene rubber, thermoplastic polyolefin elastomer, styrene block copolymer, and combinations thereof;
at least 10% by weight of a first tackifying agent that includes from 0% by weight to less than 15% by weight aromaticity based on the weight of the first tackifying agent, the first tackifying agent being selected from the group consisting of aliphatic tackifying agent, aromatic-modified aliphatic tackifying agent, cycloaliphatic tackifying agent, aromatic-modified cycloaliphatic tackifying agent, and combinations thereof;
a second rosin-based tackifying agent; and
a liquid butene component selected from the group consisting of polyisobutylene, polyisobutene, polybutene, and combinations thereof.
US Pat. No. 10,967,346

MICROSPHERES AND METHOD FOR PRODUCING THEM

Shenkar Engineering Desig...

1. A method for producing a plurality of microsphere having an average diameter of less than 500 ?m in diameter and an average contact angle ?c greater than 140°, the method comprising:heating and mixing a polymeric carrier vehicle with at least one payload substance to obtain a molten mixture free of organic solvent; dispensing microportions of the molten mixture through an orifice of a droplet-forming space onto a solid superoleophobic surface; and
allowing the dispensed microportions to stabilize on the superoleophobic surface,
wherein said polymeric carrier vehicle is biocompatible and has a melting point of about 45° C. to 200° C.;
wherein the payload has a melting point suitable to be dissolved or dispersed in the molten mixture;
wherein the payload has thermal stability in the molten mixture;
wherein the payload is solid or liquid at room temperature;
wherein said molten mixture has a viscosity between about 100 mPas and about 2,500 mPas;
wherein stabilization of the microportions is within a time period of a fraction of a second, whereby said plurality of microspheres are formed.
US Pat. No. 10,969,396

IN VITRO METHOD, USE OF AN AGENT AND COLLECTION DEVICE FOR THE INHIBITION OF COAGULATION IN BLOOD

Petra Weser-Bisse, Denzl...

1. A method for collecting and analyzing and optionally storing blood in vitro, comprising:providing a blood collection device,
mixing blood after its withdrawal in said blood collection device with citric acid as the only anticoagulant, wherein said citric acid is provided as a free acid having a pKa of >0.9, wherein the concentration of said citric acid provided as free acid having a pKa of >0.9 is at least 0.1 mmol/L of blood mixed therewith, wherein the citric acid comprises three carboxyl groups per molecule,
wherein said mixing is carried out under conditions that in the citric acid as provided, all of the carboxyl groups in the molecule are protonated,
wherein coagulation in blood is thereby inhibited,
wherein the blood, collected in a single device and mixed with citric acid and optionally after being stored in the blood collection device for a desired period of time, is subsequently subjected to at least one test for the determination of at least one blood component, and further to multiple tests comprising at least one hematologic test, at least one coagulation test and at least one further clinical chemistry analysis.
US Pat. No. 10,968,373

EPOXY ADHESIVE COMPOSITION

SEKISUI CHEMICAL CO., LTD...

1. An epoxy adhesive composition comprising:a modified polyvinyl acetal resin having a constitutional unit with an acid-modified group; and
an epoxy resin,
the epoxy adhesive composition containing an organic solvent in an amount of 10.0% by weight or less and an amount of the epoxy resin of 45% by weight to 99.5% by weight,
wherein a ratio between the number of the acid-modified groups contained in the modified polyvinyl acetal resin and the number of epoxy groups contained in the epoxy resin is 0.0005 to 0.5.
US Pat. No. 10,968,629

MINERAL FIBRE BOARD

Knauf Insulation, Inc., ...

1. A method of manufacturing a mineral fiber insulating board comprisingi) spraying a formaldehyde free aqueous binder solution onto a plurality of mineral fibers, the aqueous binder solution comprising binder reactants comprising a) a reducing sugar reactant; and b) an amine reactant, wherein the reducing sugar reactant is selected from the group consisting of: a reducing sugar; a reducing sugar yielded by a carbohydrate in situ under thermal curing conditions; and combinations thereof, wherein the percent by dry weight of the reducing sugar reactant with respect to the total weight of the binder reactants in the binder solution ranges from about 73% to about 96%, and wherein the percent by dry weight of the amine reactant with respect to the total weight of the binder reactants in the binder solution ranges from about 4% to about 27%,
ii) dehydrating the aqueous binder solution such that a dehydrated binder is disposed on the plurality of mineral fibers, and
iii) curing the dehydrated binder on the plurality of mineral fibers to provide the mineral fiber insulating board with a cured binder in about 0.5%-15% by weight as determined by loss on ignition, wherein
a) the mineral fiber insulating board has a density from about 100 kg/m3 to about 200 kg/m3,
b) the mineral fiber insulating board has an ordinary compression strength of at least 60 kPa,
c) the mineral fiber insulating board has a weathered compression strength of at least 40 kPa, and
d) the mineral fiber insulating board has a change in thickness of less than 2% after autoclave, and wherein the mineral fibers are rock wool mineral fibers.
US Pat. No. 10,968,119

WATER TREATMENT PROCESS

U.S. Clean Water Technolo...

1. A process to recover salts of naphthalenic acid from an aqueous stream comprising the steps of:a) adjusting the pH of the naphthalenic salts with an aqueous diluent,
b) optionally adding a hydrocarbon diluent,
c) treating the naphthalenic soap derivative in aqueous diluent with an electrical field such that the naphthalenic acid coalesces into larger droplets and,
d) recovering the larger droplets, thereby removing at least 50% of the naphthalenic acid from the oil stream,
e) oxidizing any soluble forms of the naphthalenic salt or any other organics by hydroxy and peroxide groups or other reactive oxygen species,
f) formed by an electric field generated by at least one electrode comprising titanium and/or the at least one electrode comprising coatings of ruthenium oxide or iridium oxide or combinations applied to said titanium electrode.
US Pat. No. 10,968,375

SILICONE RUBBER COMPOSITION AND COMPOSITE MADE THEREFROM

DOW TORAY CO., LTD., Tok...

1. A silicone rubber composition comprising:(A) 100 parts by mass of an organopolysiloxane having at least two alkenyl groups in a molecule and free of an aryl group;
(B) 0.1 to 5 parts by mass of (B-1) an organosiloxane having in a molecule at least one silicon-bonded aryl group, at least one silicon-bonded hydrogen atom, and free of an alkenyl group, or a mixture of component (B-1) and (B-2) an organosiloxane having in a molecule at least one aryl group and at least one alkenyl group;
(C) 0.1 to 5 parts by mass of an acrylic or a methacrylic compound;
(D) an organopolysiloxane having at least two silicon-bonded hydrogen atoms in a molecule and free of an aryl group and an alkenyl group, in an amount such that a mole ratio of silicon-bonded hydrogen atoms per 1 mole of total aliphatic unsaturated bonds in the silicone rubber composition is 0.5 to 5; and
(E) a catalytically effective amount of a hydrosilylation reaction catalyst.
US Pat. No. 10,968,376

OIL-ENHANCED POLYMER MODIFIED ASPHALT ADHESIVE COMPOSITIONS AND METHODS OF MAKING

Owens Corning Intellectua...

1. A method for producing an oil-enhanced polymer modified asphalt adhesive composition, the method comprising:heating an asphalt to a temperature above 300° F. to form a heated asphalt;
incorporating an oil or oil derivative additive into the heated asphalt, to form an oil-enhanced asphalt composition;
incorporating a polymer modifier into the oil-enhanced asphalt composition to form an oil-enhanced polymer modified asphalt composition; and
incorporating at least one filler, into the oil-enhanced polymer modified asphalt composition to form an oil-enhanced polymer modified asphalt adhesive composition,
wherein the oil comprises one or more of vegetable oils, nut oils, and seed oils;
wherein oil-enhanced polymer modified asphalt adhesive composition comprises:
25 to 60 percent by weight of the at least one filler material;
1 to 10 percent by weight of the polymer modifier; and
1.0 to 8.0 percent by weight of the oil or oil derivative additive; and
wherein oil-enhanced polymer modified asphalt adhesive composition has a penetration of from about 50 to about 150 pen units at 25° C. with a 100 gram weight and a softening point from about 155° F. to about 282° F.
US Pat. No. 10,967,351

FLUID CATALYTIC CRACKING PROCESS

Hindustan Petroleum Corpo...

1. A fluid catalytic cracking unit (FCCU) for production of petrochemical feedstock fractions, the FCCU comprising:a first reactor to receive a stream of desalinated crude oil and a first stream of a regenerated catalyst and produce a first cracked product stream;
a second reactor to receive a stream of light cracked naphtha (LCN) and a second stream of the regenerated catalyst to produce a second cracked product stream;
a third reactor to receive a bottom stream and a third stream of the regenerated catalyst to obtain a third cracked product stream; and
a fractionating column and gas concentration section to separate components of the first cracked product stream, the second cracked product stream and the third cracked product stream to produce a gas fraction, a cracked naphtha stream, a cycle cut oil stream, and the bottom stream,
wherein the LCN received by the second reactor is obtained from the cracked naphtha stream, and
wherein the gas fraction and the cracked naphtha stream are further fractionated to obtain Ethylene, Propylene, Butylene, Benzene, Toluene and Xylene as the petrochemical feedstock fractions.
US Pat. No. 10,968,378

HALOOLEFIN-BASED COMPOSITION

DAIKIN INDUSTRIES, LTD., ...

1. A freezer comprising a haloolefin-based composition, the haloolefin-based composition comprising:(a) HFO-1234yf;
(b) HFO-1234ze in an amount of 0.1 ppm by weight or more and 10,000 ppm by weight or less based on the total amount of the (a) HFO-1234yf;
(c) water in an amount of 3 ppm by weight or more and 200 ppm by weight or less based on the total amount of the (a) HFO-1234yf; and
(d) oxygen in an amount of more than 0 mol % and 0.35 mol % or less based on the total amount of the (a) HFO-1234yf.
US Pat. No. 10,968,379

HEAT-STORAGE COMPOSITION

DIC Corporation, Tokyo (...

1. A heat-storage composition, comprising:a resin;
a heat storage material; and
a plasticizer,
wherein the composition has a viscosity of 100 decipascal seconds (dPa·s) to 1,000 dPa·s, as measured with a cylinder-type rotational viscometer, and a storage elastic modulus (G?) of 3 Pa or more at an angular frequency of 1 rad/s, as measured by a dynamic viscoelasticity measurement method at a temperature of 25° C. and at a strain of 0.1%, and
wherein a HSP distance between the heat storage material and the plasticizer is 6 or more and 40 or less.
US Pat. No. 10,967,098

DRUG CONJUGATED NANOGELS IN MICROCAPSULE FOR DELAYED SUSTAINED PROTEIN DELIVERY

1. A composition for tissue engineering comprising;a plurality of first nanogels, each first nanogel including a first crosslinked degradable polymer conjugated to a first signaling molecule, the first degradable polymer comprising a first polyethylene glycol having a first molecular weight, the first signaling molecule stimulating formation or repair of a biological tissue, the first molecular weight of the first polyethylene glycol providing a first degradation rate to the first nanogel;
a plurality of first microcapsules, each first microcapsule carrying a plurality of the first nanogels, the first microcapsules each comprising a shell that includes a first bioerodable polymer;
a plurality of second nanogels, each second nanogel including a second crosslinked degradable polymer conjugated to a second signaling molecule, the second degradable polymer comprising a second polyethylene glycol having a second molecular weight, the second signaling molecule stimulating formation or repair of the biological tissue, the second molecular weight of the second polyethylene glycol providing a second degradation rate to the second nanogel, the second degradation rate differing from the first degradation rate;
a plurality of second microcapsules, each second microcapsule carrying a plurality of the second nanogels, the second microcapsules each comprising a shell that includes a second bioerodable polymer;
a crosslinkable polymer.
US Pat. No. 10,968,380

CROSSLINKED SYNTHETIC POLYMER-BASED RESERVOIR DRILLING FLUID

SCHLUMBERGER TECHNOLOGY C...

1. A method of drilling a wellbore, comprising:pumping an alkaline wellbore fluid into a wellbore through an earthen formation, the alkaline wellbore fluid comprising:
a base fluid; and
a crosslinked and branched polymeric fluid loss control agent formed from at least an acrylamide monomer and a sulfonated anionic monomer;
wherein the fluid loss control agent has an extent of crosslinking that is selected so that the fluid loss control agent has a viscosity that is within a peak viscosity response of a viscosity response curve, wherein the peak viscosity response is defined as having an amount of crosslinker that correlates to the peak viscosity amount plus or minus the amount of crosslinker that correlates to up to 75% of the area under the viscosity response curve, and wherein the viscosity response curve for the crosslinked and branched polymeric fluid loss control agent is determined by plotting viscosity as a function of crosslinker under otherwise constant conditions; and
operating a drilling tool in the wellbore during the pumping.
US Pat. No. 10,967,099

COMPOSITE BONE IMPLANT MATERIAL AND METHOD OF MAKING THEREOF

SICHUAN NATIONAL NANO TEC...

1. A bone implant composite, comprising:a multivariant amino acid polymer and a medically acceptable organic calcium/phosphorus salt, and a content of the organic calcium/phosphorus salt is 60% based on a total mass of the composite,
wherein a molar ratio of calcium and phosphorus combined in said organic calcium/phosphorus salt is in a range of 1.5-1.67,
wherein the medically acceptable organic calcium/phosphorus salt is calcium tartrate-fructose diphosphate dicalcium; and the multivariant amino acid polymer is polymerized by ?-aminocaproic acid, lysine, proline, and ?-aminobutyric acid, and
wherein a molar content of ?-aminocaproic acid is at least 50% of a total molar quantity of the multivariant amino acid polymer and a molar content of lysine or proline is at least 0.5% of the total molar quantity of the multivariant amino acid polymer.
US Pat. No. 10,968,125

NON-DISSOLVED REDOX MEDIATOR BIOFILM CARRIER AND ITS PREPARATION METHOD

DALIAN UNIVERSITY OF TECH...

1. A preparation method for a non-dissolved redox mediator biofilm carrier, comprising the following steps:1) adjusting a pH of a first dispersion of the graphene oxide to 8-12 by using ammonia water, thereafter the dispersion is having hydrothermal reaction at 60-100° C. for 3-9 hours, and then cooling down and drying the dispersion at a temperature less than or equal to 60° C. to obtain solid N-GO particles;
2) adding the solid N-GO particles obtained in step 1) to water, and uniformly dispersing by ultrasonication to obtain a second dispersion, then adding an oxidant to the second dispersion under acidic condition in ice-water bath, stirring for 3 hours and drying to obtain carboxylation modified graphene oxide Q-GO solid particles; wherein the mass ratio of N-GO, water, acid and oxidant is 1:50-150:20-60:3-8;
3) ultrasonically dispersing the non-dissolved redox mediator material in a solvent to obtain a third dispersion, then adding a basic material to the third dispersion and soaking it for 1-4 hours, including stirring every half an hour to make the redox mediator fully contact with the basic material, then drying the third dispersion at 60-80° C. to obtain a solid mixture;
wherein the non-dissolved redox mediator, as the functional material, is the graphene oxide and/or carboxylation modified graphene oxide;
wherein the basic material is extrusion grade polyethylene/polypropylene particles;
4) extruding the solid mixture obtained in step 3), by using a screw extruder; the processing temperature of each section of the screw extruder is 120° C. to 190° C. to ensure that the basic material is fully mixed with the non-dissolved redox mediator material in a molten state, for melt extrusion molding;
wherein the non-dissolved redox mediator biofilm carrier, comprises:
a non-dissolved redox mediator as a functional material, and
a basic material;
the non-dissolved redox mediator is graphene oxide and/or carbonylation modified graphene oxide, and the basic material is extrusion grade polyethylene/polypropylene particles;wherein the mass ratio of the functional material to the basic material is lower than 1:2.5.
US Pat. No. 10,966,588

ANTIMICROBIAL HYDROPHILIC POLYURETHANE FOAM SPONGES

3M INNOVATIVE PROPERTIES ...

1. A hydrophilic polyurethane foam sponge, comprising:an antimicrobial composition including an acetate salt solution humectant.
US Pat. No. 10,967,100

METHODS OF MAKING A LAYERED CONSOLIDATED UHMWPE COMPRISING A PHARMACEUTICAL COMPOUND

THE GENERAL HOSPITAL CORP...

1. A method of making a layered consolidated UHMWPE for use as a medical implant, wherein the method comprises the steps of:blending ultrahigh molecular weight polyethylene (UHMWPE) powder, flakes or particles with at least one additive to provide a UHMWPE blend;
drying the UHMWPE blend from the blending step;
consolidating as layers the UHMWPE blend from drying step with a second UHMWPE to yield layered consolidated UHMWPE comprising the additive in at least one layer; and
machining the layered consolidated UHMWPE, wherein the additive is a pharmaceutical compound.
US Pat. No. 10,967,356

DUAL LIGAND SOL-GEL SORBENT COMBINING SUPERHYDROPHOBICITY AND ?-? INTERACTION

University of South Flori...

1. A dual ligand sol-gel sorbent for use in solid phase microextraction (SPME) comprising:at least two sol-gel precursors wherein the sol-gel precursors are a perfluorododecyl (PF-C12) ligand and a phenethyl ligand;
an inorganic co-precursor; and
a catalyst wherein the catalyst is trifluoroacetic acid (TFA);
wherein the dual ligand sol-gel provides enhanced extraction capability for aliphatic hydrocarbons, aromatic hydrocarbons, and nonpolar derivatives thereof.
US Pat. No. 10,967,357

ENHANCED SORBENT FORMULATION FOR REMOVAL OF MERCURY FROM FLUE GAS

CALGON CARBON CORPORATION...

1. A mercury sorbent comprising:a dry admixture comprising separate and distinct particles of
an adsorptive material comprising one or more of carbonaceous char, activated carbon, carbon black, reactivated carbon, zeolite, and alumina clay; and
a non-halogen ammonium-containing compound;
wherein the mercury sorbent has no halogen containing component.
US Pat. No. 10,967,358

COMPOSITE GRANULES INCLUDING POLYMERIC SORBENT FOR ALDEHYDES

3M Innovative Properties ...

1. Composite granules comprising:a polymeric sorbent comprising a reaction product of
(a) a precursor polymeric material comprising a free radical polymerization product of a polymerizable composition comprising
(1) 20 to 65 weight percent maleic anhydride based on the total weight of monomers in the polymerizable composition;
(2) 30 to 85 weight percent divinylbenzene based on the total weight of monomers in the polymerizable composition; and
(3) 0 to 40 weight percent of a styrene-type monomer based on the total weight of monomers in the polymerizable composition, wherein the styrene-type monomer is styrene, an alkyl-substituted styrene, or a combination thereof; and
(4) a free radical initiator; and
(b) a nitrogen-containing compound that is selected from ammonia, a compound having a single primary amino group (—NH2), or a compound having at least two amino groups of formula —NHR where R is hydrogen or alkyl; and
a binder, wherein the binder is blended with particles of the polymeric sorbent and wherein multiple particles of the polymeric sorbent are held together by the binder in the composite granules.
US Pat. No. 10,968,640

STONE-PLASTIC HOT PRESSING FLOORING AND MANUFACTURING METHOD THEREOF

ZHEJIANG KINGDOM PLASTICS...

1. A manufacturing method of stone-plastic hot pressing flooring, wherein the stone-plastic hot pressing flooring comprisesa stone-plastic base material part, comprising a middle material layer, a stone-plastic substrate layer, and a bottom material layer sequentially arranged side by side;
a color film layer, located at one side of an upper surface of the stone-plastic base material part;
a first wear-resistant layer, located at one side of an upper surface of the color film layer; and
a second wear-resistant layer, located at one side of a lower surface of the stone-plastic base material part;
wherein both the middle material layer and the bottom material layer are mainly composed of polyvinyl chloride, plasticizer, stabilizer, carbon black, and stone powder,
the manufacturing method comprising the following steps:
adding and mixing raw materials of the bottom material layer to obtain a bottom material layer intermediate, and then internal-mixing and calendering the bottom material layer intermediate to obtain a bottom material layer sheet;
adding and mixing raw materials of the middle material layer to obtain a middle material layer intermediate, and then internal-mixing and calendering the middle material layer intermediate to obtain a middle material layer sheet;
mixing, internal-mixing, and calendering raw materials of the stone-plastic substrate layer to obtain a stone-plastic substrate layer sheet;
sequentially arranging a first wear-resistant layer film, a color film, the middle material layer sheet, the stone-plastic substrate layer sheet, the bottom material layer sheet, and a second wear-resistant layer film, and then carrying out a hot pressing process to obtain a finished product; and
a cold pressing process, wherein the cold pressing process is carried out after the hot pressing process and comprises a first cold pressing process and a second cold pressing process.
US Pat. No. 10,971,718

ELECTROCHEMICAL ENERGY STORAGE DEVICES

GENTEX CORPORATION, Zeel...

14. A energy storage device comprising:a first cell comprising an anodic material in an activated state;
a second cell comprising a cathodic material in an activated state;
a porous separator isolating the first cell from the second cell; and
wherein:
the cathodic material is a ferrocenium compound or 1,2,4,5-tetracyanobenzene; and
the anodic material is a phenazine, a phenothiazine, a triphenodithiazine, a carbazole, a indolocarbazole, a biscarbazole, or a ferrocene.
US Pat. No. 10,967,359

POLYMERIC SORBENTS FOR REACTIVE GASES

3M Innovative Properties ...

1. A polymeric sorbent comprising a reaction product of:(a) a precursor polymeric material comprising a polymerized product of a polymerizable composition comprising
(1) 8 to 65 weight percent maleic anhydride based on the total weight of monomers in the polymerizable composition;
(2) 30 to 85 weight percent divinylbenzene based on the total weight of monomers in the polymerizable composition; and
(3) 0 to 20 weight percent of a styrene-type monomer based on the total weight of monomers in the polymerizable composition, wherein the styrene-type monomer is styrene, an alkyl-substituted styrene, or a combination thereof; and
(b) a nitrogen-containing compound that is selected from ammonia or a compound having at least one primary amino group or at least one secondary amino group, the nitrogen-containing compound being of Formula (IV) or Formula (V)
R3NHR2  (IV)
R7—(NHR2)z  (V)whereinR2 is hydrogen or an alkyl;
R3 is hydrogen, alkyl, a group of formula —R4—NR5R6, or —(C?NH)—NH2;
R4 is a covalent bond, an alkylene, an arylene, an aralkylene, a heteroalkylene having one or more oxy (—O—) groups, or a heteroalkylene having one or more —NH— groups;
R5 is hydrogen or alkyl; and
R6 is hydrogen, alkyl, or —(C?NH)—NH2;
R7 is a z-valent radical of an alkane or a z-valent radical of a heteroalkane;
z is an integer in a range of 3 to 10; and
the polymeric sorbent has covalently attached nitrogen-containing groups.
US Pat. No. 10,967,360

GELS FOR REMOVING AIR POLLUTANTS

Honeywell International I...

1. A gel for removing one or more air pollutants from air, comprising:at least one polymer;
at least one adsorbent;
at least one chelating agent chosen from sodium tripolyphosphate, sodium polyphosphate, sodium hexametaphosphate, sodium pyrophosphate, nitrilotriacetic acid, diethylene triamine pentaacetic acid, ethylene glycol-bis-(?-aminoethyl ether)-N,N-tetraacetic acid, tetrasodium vinoxy diphosphate, aminotrimethylene phosphonate, and mixtures thereof;
at least one component that reacts with at least one air pollutant; and
water.
US Pat. No. 10,967,618

CURABLE COMPOSITION FOR FORMING PRIMER LAYER, GAS BARRIER LAMINATED FILM, AND GAS BARRIER LAMINATE

LINTEC CORPORATION, Toky...

1. A gas barrier laminate, comprising an organic compound-containing layer laminated on a primer layer constituting an outermost layer of a gas barrier laminated film, wherein the gas barrier laminated film comprises a gas barrier layer and the primer layer in direct contact with the gas barrier layer, whereinthe gas barrier layer is made of a gas barrier film,
the primer layer is made of a cured product of a curable composition comprising at least a polar group-containing polyolefin polymer, a polyfunctional acrylate compound, and a silane coupling agent and,
the organic compound-containing layer is a protective layer, an adhesive layer, or a quantum dot layer.
US Pat. No. 10,967,363

TWO-DIMENSIONAL METAL CARBIDE CATALYST

Iowa State University Res...

1. A catalyst comprising platinum and a MXene comprising Formula I:Mn+1Xn  (I)whereinn is 1, 2, or 3;
M is an early transition metal; and
X is carbon, nitrogen or CN;
wherein the platinum is bonded to the early transition metal (M) via a metal-metal bond to form an intermetallic alloy; and
wherein the intermetallic alloy has the formula Pt3M and an L12 type crystal structure.
US Pat. No. 10,968,134

LOW VISCOSITY GLASSES AND METHODS AND SYSTEMS FOR MANUFACTURE

Corning Incorporated, Co...

1. A glass article having a fusion line and comprising on an oxide basis:from greater than or equal to 60 mol % to less than or equal to 74 mol % SiO2;
from greater than or equal to 7 mol % to less than or equal to 18 mol % Al2O3;
from greater than or equal to 3 mol % to less than or equal to 16 mol % B2O3;
from greater than or equal to 0 mol % to less than or equal to 5 mol % P2O5;
from greater than or equal to 0 mol % to less than or equal to 0.2 mol % SnO2;
from greater than or equal to 5 mol % to less than or equal to 11 mol % Li2O;
from greater than 0 mol % to less than or equal to 6 mol % Na2O; and
from greater than or equal to 0 mol % to less than 0.1 mol % K2O;wherein the glass article has a strain point from greater than or equal to 515° C. to less than or equal to 625° C.
US Pat. No. 10,967,110

SYSTEM AND METHODS FOR PREPARATION OF ADIPOSE-DERIVED STEM CELLS

Jointechlabs, Inc., Nort...

1. A tissue processing device comprising:a first centrifuge tube configured to receive and process a biological substance, the first centrifuge tube comprising an upper cylindrical portion and a lower conical portion, a sterile tissue inlet fitting, at least one sterile processing fluid inlet fitting, a sterile suction fitting, and at least one sterile extraction port connected to a first extraction tube;
wherein the first centrifuge tube further comprises an internal space including a screen being positioned therein, the screen being configured to divide the internal space, and a filter positioned therein, the filter being positioned below the screen in the lower conical portion of the first centrifuge tube; and
a second centrifuge tube configured to receive and further process the biological substance from the first centrifuge tube, the second centrifuge tube comprising at least one sterile fitting, wherein the second centrifuge tube is releasably connected via the at least one sterile fitting to one of the at least one sterile extraction ports of the first centrifuge tube.
US Pat. No. 10,967,367

METHOD OF CLEANING RESINS

DDP SPECIALTY ELECTRONIC ...

1. A method of cleaning a collection of resin beads, wherein the method comprises bringing the collection of resin beads into contact with an aqueous solution, wherein the aqueous solution comprises one or more dissolved amine compounds, wherein the collection of resin beads comprises polymer that comprises attached carboxylic acid groups or sulfonic acid groups or a mixture thereof.
US Pat. No. 10,968,141

CONCRETE MANUFACTURING METHOD USING NITROGEN DISSOLVED WATER AND METHOD FOR MANUFACTURING REINFORCED CONCRETE STRUCTURE

Showa Freezing Plant Co.,...

1. A concrete manufacturing method using nitrogen dissolved water, the method comprising the steps of:compressing atmospheric air to provide compressed air;
purging oxygen from the compressed air to generate a nitrogen gas;
substituting oxygen and carbon dioxide that are dissolved in water with nitrogen by injecting the nitrogen gas into water to generate the nitrogen dissolved water; and
kneading the nitrogen dissolved water, cement, an aggregate, and an admixture to generate ready-mixed concrete.
US Pat. No. 10,969,678

SYSTEM AND METHOD FOR PRODUCING AN OPTICAL MASK FOR SURFACE TREATMENT, AND SURFACE TREATMENT PLANT AND METHOD

H.E.F., Andrezieux Bouth...

1. A system for producing an optical mask for surface treatment, the system comprising:a layer of material which has an outer surface that is exposed to the outside environment; and
a generating and depositing device for generating and depositing droplets on the outer surface of the layer of material, in a specific arrangement, forming the optical mask on the outer surface of the layer of material,
wherein the outer surface of the layer of material is initially treated thereby defining preferential fixing sites of the droplets, thus enabling the arrangement of the droplets forming the optical mask on the outer surface to be controlled.
US Pat. No. 10,968,398

METHOD FOR PRODUCING KETONES FOR FUEL AND OIL APPLICATIONS

NESTE OYJ, Espoo (FI)

1. A method for producing ketones, suitable for manufacture of base oil or diesel fuel components, from a feedstock of biological origin containing fatty acids or fatty acid derivatives, wherein the feedstock is at least partly in liquid phase, the method comprising:introducing the feedstock into a ketonisation reactor together with a carrier gas stream containing CO2;
subjecting the feedstock to a catalytic ketonisation reaction, wherein the ketonisation reaction is carried out in a system having one or more ketonisation reactor(s) each with at least one ketonisation catalyst bed;
separating gas containing CO2 from an effluent exiting a ketonisation reactor whereby the effluent containing ketones is used either as a feedstock for a further ketonisation reactor or for recovery of ketones from the effluent; and
recycling the separated gas containing CO2 for use in the carrier gas stream in a ketonisation reactor.
US Pat. No. 10,969,679

SYSTEM AND METHOD FOR PRODUCING AN OPTICAL MASK FOR SURFACE MICROTEXTURING, AND SURFACE MICROTEXTURING PLANT AND METHOD

H.E.F., Andrezieux Bouth...

1. A system for producing a mask for surface microtexturing, the system comprising:a substrate having a surface to be textured;
a layer of material made from photosensitive material which covers the surface of the substrate and has an outer surface that is exposed to the outside environment;
a generating and depositing device for generating and depositing droplets on the outer surface of the layer of material, in a specific arrangement by condensation, forming an optical mask on the outer surface of the layer of material, and
a localized removal device for localized removal of the layer of material, based on the arrangement of the droplets forming the optical mask on the outer surface of the layer of material, which then includes removal zones and material zones forming a second mask on the substrate,
wherein the localized removal device for the layer of material comprises an exposure unit emitting a light flow that passes through the droplets and reaches the outer surface of the layer of material, and a unit for developing the layer of material after exposure to the light flow,
wherein the exposure unit comprises a light source that is tilted relative to a direction normal to the outer surface of the layer of material, and the light flow passes through the droplets and reaches the outer surface of the layer of material under oblique incidence.
US Pat. No. 10,968,145

METHOD TO PREPARE A SOY HYDROLYSATE PRODUCT WITH A HIGH CONCENTRATION OF FREE AMINO ACIDS AND METHOD OF USING THE SAME

Nachurs Alpine Solutions,...

1. A method of treating soil or turf grasses, the method comprising:a. providing a potassium salt of a soy hydrolysate prepared by reacting soy meal with a diluted hydrochloric acid solution until the pH of the reaction mixture is below pH 1 and concurrently heating the reaction mixture to a temperature of at least 60° C. (140° F.) for a period of time of up to forty-eight hours, and then cooling the reaction mixture to ambient temperature and adding a base to raise the pH to at least pH 3, and then filtering the solution and recovering a free amino acid soy hydrolysate liquid composition;
b. providing soil or turf grass for treatment;
c. applying the free amino acid soy hydrolysate composition to the soil or turf grass at a concentration of from 0.1 pounds of liquid per 1000 square feet to 100 pounds of liquid per 1000 square feet;
d. allowing the hydrolysate composition to react with the soil or turf grass; and,
e. re-applying the hydrolysate composition to the soil or turf grass at predetermined intervals.
US Pat. No. 10,968,147

PYROTECHNIC AGENT

RUAG AMMOTEC GMBH, Furth...

1. A pyrotechnic consisting of 20 to 50 wt. % of at least one azotetrazolate component selected from the group consisting of aminoguanidine-5,5?-azotetrazolate (AGATZ) and guanidine-5,5?-azotetrazolate (GATZ), and 50 to 80 wt. % of at least one additive selected from the group consisting of ammonium picrate, aminoguanidinium picrate, guanidinium picrate, aminoguanidinium styphnate, guanidinium styphnate, nitroguanidine, nitroaminoguanidine, nitrotriazolone, derivatives of tetrazole and/or its salts, nitraminotetrazole and/or its salts, aminoguanidine nitrate, diaminoguanidine nitrate, triaminoguanidine nitrate, guanidine nitrate, dicyandiamidine nitrate, diaminoguanidine azotetrazolate, nitrates of alkali and/or alkaline-earth metals and/or of ammonium, perchlorates of alkali and/or alkaline-earth metals and/or of ammonium, peroxides of alkali and/or alkaline-earth metals and/or of zinc, aluminium, titanium, titanium hydride, boron, boron hydride, zirconium, zirconium hydride, silicon, graphite, activated charcoal, carbon black, cellulose and/or its derivatives, polyvinylbutyrals, polynitropolyphenylene, polynitrophenyl ether, plexigum, polyvinyl acetate and copolymers, hexogen, octogen, nitrocellulose, ferrocene and/or its derivatives, acetonylacetates, salicylates, carbonates, melamine, silicates, silica gels, and boron nitride, wherein a deflagration temperature of the pyrotechnic agent in a range from 165° C. to 195° C.
US Pat. No. 10,968,408

GASOLINE COMPOSITION AND PRODUCTION PROCESS THEREFOR

IDEMITSU KOSAN CO., LTD, ...

1. A gasoline composition comprising 0.3 to 10.0 vol % of hemicellulose-derived pentene, 3.08 to 12.0 vol % of a pentene content including the hemicellulose-derived pentene, 1.0 to 23.0 vol % of cellulose-derived hexene, and 3.72 to 27.0 vol % of a hexene content including the cellulose-derived hexene,and having a ratio of (2-pentene content) to (1-pentene content) of 3.0 to 7.0 vol %/vol %, and a ratio of (2-hexene content) to (1-hexene content) of 6.50 to 9.0 vol %/vol %,
wherein the gasoline composition has a density at 15° C. of 0.7100 to 0.7300 g/cm3, a vapor pressure of 44.0 to 93.0 kPa, a 10% distillation temperature of 38.0 to 60.0° C., a 50% distillation temperature of 75.0 to 100.0° C., a 90% distillation temperature of 110.0 to 170.0° C., and an oxidation stability of not less than 240 minutes, wherein the oxidation stability is measured in accordance with JIS K 2287 “Gasoline-Determination of oxidation stability-Induction period method”.
US Pat. No. 10,968,154

DERIVITIZATION OF VAPOROUS CHLORINE BY PROPYLENE OXIDE

The Government of the Uni...

6. A method comprising:providing a fiber having ethylene oxide adsorbed thereon;
exposing the fiber to a gaseous sample;
allowing the ethylene oxide to react with any chlorine and water vapor in the sample to form chloro-2-ethanol.
US Pat. No. 10,968,155

METHOD OF DETERMINING THE INERTNESS OF MATERIALS FOR USE IN MONOMER PRODUCTION

Rohm and Haas Company, P...

1. A process for selecting an inert material for use in monomer production comprising the steps of:(a) providing a gaseous mixture (P1) comprising propylene, acrolein, and acrylic acid;
(b) feeding P1 in the vapor phase at a pressure from 1 to 1.5 atm to a fixed bed reactor tube containing the inert material having a bed temperature from 200 to 450° C. for a contact time of at least 3 seconds, to produce a second mixture (P2) comprising acrolein and acrylic acid;
(c) selectively condensing components of P2 having a boiling point at a pressure of 1 atm of at least 20° C.;
(d) analyzing the condensed components for phthalic acid, acrolein, and acrylic acid;
(e) based on the analysis, determining the PTAinert of the inert material, wherein PTAinert is the ratio of the mass of phthalic acid in P2 to the total mass of acrolein and acrylic acid collected from P2;
(f) determining the PTAempty of a fixed bed reactor tube not containing an inert material by repeating steps (a) through (d) except that the fixed bed reactor tube does not contain an inert material, wherein the PTAempty is the ratio of the mass of phthalic acid in P2 to the total mass of acrolein and acrylic acid collected from P2; and
(g) selecting the inert material for use in monomer production if the PTAinert is less than or equal to the PTAempty.
US Pat. No. 10,968,156

PROCESS FOR THE MANUFACTURING OF A 3-HALOPROPIONYL HALIDE IN A FLOW REACTOR

3M Innovative Properties ...

1. A process for the manufacturing of a 3-halopropionylhalide, wherein the process comprises the steps of:a) providing a flow reactor comprising a reaction chamber;
b) providing reactants comprising:
i. acrylic acid;
ii. a reaction co-agent selected from the group consisting of N,N- disubstituted amides; and
iii. a halogenating agent; and
c) incorporating the reactants into the reaction chamber of the flow reactor, thereby forming a reaction product stream comprising a 3-halopropionylhalide; wherein the molar ratio of acrylic acid to the halogenating agent is 1 to at least 0.8; wherein the temperature of the reaction chamber of the flow reactor is in a range from greater than 60° C. to 120° C.; and wherein the residence time of the reaction product stream comprising the 3-halopropionylhalide in the reaction chamber of the flow reactor is greater than 10 minutes.
US Pat. No. 10,968,412

LUBRICANT COMPOSITION

BASF SE, Ludwigshafen am...

1. A lubricant composition comprising:a biodegradable polyalkylene glycol satisfying the biodegradability requirements set forth in OECD 301B, wherein said biodegradable polyalkylene glycol is present in an amount of at least about 30 parts by weight based on 100 parts by weight of said lubricant composition;
an inherently-biodegradable polyalkylene glycol satisfying the inherently-biodegradability requirements set forth in OECD 301B, wherein said inherently-biodegradable polyalkylene glycol is present in an amount of from about 0.1 to about 10 parts by weight based on 100 parts by weight of said lubricant composition, wherein said inherently-biodegradable polyalkylene glycol has a kinematic viscosity at 40° C. of from 130 cSt to about 5,000 cSt, when measured in accordance with ASTM D445; and
a non-biodegradable polyalkylene glycol as defined by OECD 301B wherein said non-biodegradable polyalkylene glycol satisfies the non-bioaccumulative requirements set forth in OECD 107 and is present in an amount of from about 0.1 to about 5 parts by weight based on 100 parts by weight of said lubricant composition.
US Pat. No. 10,968,157

PROCESS FOR THE SEPARATION OF FORMALDEHYDE FROM CRUDE ACRYLIC ACID

Johnson Matthey Davy Tech...

1. A process for purification of a crude product stream recovered from the production of acrylic acid by an aldolisation reaction, said product stream comprising acrylic acid, formaldehyde, water, non-condensable vapours and optionally heavy by-products; said process comprising:(a) providing the crude product stream in the vapour phase to a first separation column operated at a temperature of about 110° C. to about 150° C. and at a pressure of about 1.0 bara to about 1.5 bara to form an intermediate overhead stream comprising water, formaldehyde and methanol; and
(b) passing said intermediate overhead stream to a formaldehyde separation column operated at a temperature at a temperature of from about 60° C. to about 80° C. and at a pressure of from about 0.2 bara to about 0.8 bara to enable a stream having a higher formaldehyde concentration than the formaldehyde concentration in the intermediate overhead stream to be formed and recovered from at or near the bottom of the formaldehyde separation column as a formaldehyde enriched stream.
US Pat. No. 10,968,158

METHOD OF DETERMINING THE INERTNESS OF MATERIALS FOR USE IN MONOMER PRODUCTION

Rohm and Haas Company, P...

1. A process for determining the inertness of an inert material for use in monomer production comprising the steps of:(a) providing a gaseous mixture (P1) comprising propylene, acrolein, and acrylic acid;
(b) feeding P1 in the vapor phase at a pressure from 1 to 1.5 atm to a fixed bed reactor tube containing the inert material having a bed temperature from 200 to 450° C. for a contact time of at least 3 seconds, to produce a second mixture (P2) comprising acrolein and acrylic acid;
(c) selectively condensing components of P2 having a boiling point at a pressure of 1 atm of at least 20° C.;
(d) analyzing the condensed components for phthalic acid, acrolein, and acrylic acid; and
(e) based on the analysis, determining the PTAinert of the inert material, wherein PTAinert is the ratio of the mass of phthalic acid in P2 to the total mass of acrolein and acrylic acid collected from P2.
US Pat. No. 10,968,414

METHODS FOR REDUCING SOAP FORMATION DURING VEGETABLE OIL REFINING

ARISDYNE SYSTEMS, INC., ...

1. A method for reducing soap formation during refining of a vegetable oil, the method comprising:a. mixing an acid-treated vegetable oil with a base to neutralize free fatty acid and acid in the acid-treated vegetable oil to form a pretreated mixture;
b. passing the pretreated mixture through a low-shear reciprocating pump operating at a shear rate of less than 2,500 s?1 to increase pressure in the pretreated mixture to form a pressurized pretreated mixture; and
c. forming a reacted mixture by passing the pressurized pretreated mixture through a static hydrodynamic reactor to induce a neutralization reaction in the pressurized pretreated mixture, the neutralization reaction forms soaps in the reacted mixture, and
d. separating the soaps from the reacted mixture to form a refined vegetable oil, the refined vegetable oil comprising less than 200 ppm of the soaps.
US Pat. No. 10,968,415

CLEANING FORMULATIONS FOR CHEMICALLY SENSITIVE INDIVIDUALS: COMPOSITIONS AND METHODS

Living Clean NZ Limited, ...

1. A cleaning composition for fabrics or hard surfaces, comprising:a. water;
b. at least 0.05% by weight of an alkyl polyglucoside that contains no undesirable contaminants, wherein the undesirable contaminants are selected from the group consisting of residual petrochemical solvents, phenyl derivatives, unsafe byproducts, and combinations of the foregoing;
c. at least 0.2% by weight of a first organic solvent, the first organic solvent consisting of denatured ethanol, wherein the ethanol is biologically-derived, and wherein the denaturant is selected from the group consisting of aqueous ammonia, sodium hydroxide, potassium hydroxide and combinations of any of the foregoing;
d. an additional surfactant selected from the group consisting of:i) 0.05 to 15% by weight of an anionic surfactant selected from the group consisting of sodium alkyl sulfates;ii) 0.05 to 30% by weight of an amphoteric surfactant selected from the group consisting of trialkyl amine oxides;iii) 0.05 to 30% by weight of a zwitterionic surfactant selected from the group consisting of betaine and sulphobetaine surfactants, derivatives thereof and mixtures thereof;iv) combinations of i) and ii); andv) combinations of i), ii) and iii);e. 0-10% by weight of an organic builder;
f. 0-10% by weight of an organic pH adjuster; and
g. 0-95% of a second solvent;
wherein each of b. through g. has a pMC of at least 80%;
wherein a headspace analysis of the cleaning composition confirms that the cleaning composition reveals analyte levels of less than 1000 ?g/m3 of any VOCs, other than ethanol, which are regulated by governmental bodies;
wherein the cleaning composition has a pMC of at least 90%;
wherein c. is regarded as a specially denatured alcohol, and
wherein none of components b. and d. through g. has a vapor pressure greater than 0.1 mm Hg at 20° C.
US Pat. No. 10,968,160

SEPARATION OF PROPIONIC ACID FROM ACRYLIC ACID VIA AZEOTROPIC DISTILLATION

Eastman Chemical Company,...

1. A process comprising:supplying a feed stream to an azeotropic distillation column, wherein the feed stream comprises acrylic acid, and at least one saturated organic acid with 3 or more carbon atoms;
adding water as an entrainer to the azeotropic distillation column; and
controlling the column at a temperature and pressure such that the feed stream is separated into at least a product top stream and a product bottom stream, wherein the product top stream comprises the saturated organic acid and water and wherein the product bottom stream comprises the acrylic acid and optionally acetic acid.
US Pat. No. 10,968,416

CLEANING COMPOSITIONS AND USES THEREOF

1. A cleaning composition comprising(a) a DNase having DNA activity and at least 90% sequence identity to the polypeptide of SEQ ID NO: 3,
(b) a mannanase having mannanase activity and at least 90% sequence identity to the polypeptide of SEQ ID NO: 82, and
(c) a cleaning component.
US Pat. No. 10,968,161

SYNTHESIS AND PURIFICATION OF MUCONIC ACID ESTER FROM ALDARIC ACID ESTERS

Teknologian tutkimuskesku...

1. A method for producing muconic acid ester from aldaric acid, the method comprising:esterification of aldaric acid into aldaric acid ester,
catalytic dehydroxylation of the aldaric acid ester by heating the aldaric acid ester with a solvent and optionally an acidic catalyst in a pressurized container to a temperature between 100 to 250° C. in the presence of a transition metal catalyst for a pre-determined reaction time, and
purifying the produced muconic acid ester in a total heating environment.
US Pat. No. 10,971,752

COMPOSITE CATHODE AND LITHIUM-ION BATTERY COMPRISING SAME, AND METHOD FOR PRODUCING SAID COMPOSITE CATHODE

Bayerische Motoren Werke ...

1. A composite cathode comprising:a collector,
an active cathode material,
a binder,
a solid inorganic lithium ion conductor, and
a liquid electrolyte,
wherein the binder is selected from the group consisting of polyvinylidene fluoride, copolymer of polyvinylidene fluoride and hexafluoro-propylene, polyethylene oxide, copolymer of styrene and butadiene, cellulose, cellulose derivatives, and mixtures thereof,
wherein the solid inorganic lithium ion conductor is selected from the group consisting of perovskite, glass formers, garnet, and mixtures thereof,
wherein the solid inorganic lithium ion conductor is present in the composite cathode in a higher volume fraction and weight fraction than the liquid electrolyte,
wherein the solid inorganic lithium ion conductor is present at 20 to 40 wt % in the composite cathode in relation to the active cathode material,
wherein 0.1 to 6 wt % of carbon-containing compounds or carbon are included in the active cathode material,
wherein the composite cathode has a porosity of 5% to 25%, based on a volume without the liquid electrolyte, and wherein the porosity is filled with the liquid electrolyte to an extent of more than 90%, and
wherein the porosity is achieved by calendering.
US Pat. No. 10,969,701

PELLICLE ATTACHMENT APPARATUS

ASML Netherlands B.V., V...

1. A pellicle frame attachment apparatus configured to receive a patterning device and a pellicle assembly comprising a pellicle frame and a pellicle, the pellicle attachment device comprising manipulators configured to operate an engagement mechanism of a sub-mount provided on a pellicle frame, wherein the manipulators project through or project from openings provided in a partition which separates a pellicle assembly receiving controlled environment from other parts of the pellicle frame attachment apparatus.
US Pat. No. 10,968,164

PROCESS TO CONVERT THE CYCLIC MONOUREA OF AN ETHYLENE AMINE COMPOUND INTO THE ETHYLENE AMINE COMPOUND

NOURYON CHEMICALS INTERNA...

1. A process to convert a cyclic monourea of ethylene amine compounds into an ethylene amine compound, the process comprising:performing a reactive separation step using a reaction mixture containing the cyclic monourea, wherein one cyclic monourea reacts with another cyclic monourea to transfer its urea unit thereto;
whereby the ethylene amine compound is separated from the reaction mixture.
US Pat. No. 10,969,704

MAGNETIC TONER AND METHOD FOR MANUFACTURING MAGNETIC TONER

CANON KABUSHIKI KAISHA, ...

1. A magnetic toner, comprising:a toner particle, the toner particle including a magnetic body having an oil absorption of 5 to 40 ml/100 g and a hinder resin;
the hinder resin containing a polymer A having first and second monomer units, the first monomer unit being derived from a first polymerizable monomer and the second monomer unit being derived from a second polymerizable monomer different from the first polymerizable monomer;
the first polymerizable monomer being at least one selected from the group consisting of (meth)acrylic acid esters each having a C18-36 alkyl group, and a content of the first monomer unit in polymer A being 5.0 to 60.0 mol % of the total moles of all monomer units in the polymer A; and
a content of the second monomer unit in polymer A being 20.0 to 95.0 mol % of the total moles of all monomer units in the polymer A, wherein
3.00?(SP21?SP11)?25.00 when SP11 (J/cm3)0.5 is an SP value of the first monomer unit and SP21 (J/cm3)0.5 is an SP value of the second monomer unit, and
the content of the polymer A in the binder resin is at least 50.0 mass %.
US Pat. No. 10,968,167

2,2,2-TRIFLUOROACETIC ACID 1-(2,4-DIMETHYLPHENYL)-2-[(3-METHOXYPHENYL)METHYLENE] HYDRAZIDE POLYMORPHS AND METHOD OF MAKING THE SAME

ABREXA PHARMACEUTICALS, I...

1. A method of making crystalline Form II of 2,2,2-trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide (J147), having a powder X-ray diffraction pattern comprising peaks located at 13.37, 18.47, and 23.34+/?0.2 degrees 2-theta, the method comprising:(a) providing a slurry comprising saturated amorphous or crystalline Form I of 2,2,2-trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene] hydrazide (J147) in a mixture comprising a solvent and an anti-solvent; and
(b) mixing the slurry to provide the crystalline Form II.
US Pat. No. 10,967,398

COATED ARTICLES AND METHODS OF MAKING THE SAME

GM GLOBAL TECHNOLOGY OPER...

1. A coated article, comprising:a metallic substrate;
a foundation coat bonded to the metallic substrate, wherein the foundation coat comprises:
cross-linked titania or silica nanoparticles; and
a plurality of capsules distributed among the cross linked titania or silica nanoparticles, each capsule including a shell capable of covalently bonding to the cross-linked titania or silica nanoparticles and a healing agent surrounded by the shell, wherein the healing agent is an alcohol based sol gel material comprising titania or silica nanoparticles, and wherein the shell and the healing agent are chemically compatible with the cross linked titania or silica nanoparticles.
US Pat. No. 10,968,168

ISOCYANATE PRODUCTION METHOD

Asahi Kasei Kabushiki Kai...

1. An isocyanate production method in which an isocyanate is produced by thermal decomposition of a carbamate, comprising:a step of preparing a mixture liquid comprising the carbamate and a polyisocyanate compound;
a step of conducting a thermal decomposition reaction of the carbamate by continuously introducing the mixture liquid into a thermal decomposition reactor:
a step of collecting a low-boiling decomposition product by continuously extracting the low-boiling decomposition product in a gaseous state from the thermal decomposition reactor, the low-boiling decomposition product having a standard boiling point lower than the polyisocyanate compound and comprising the isocyanate; and
a step of collecting a high-boiling component by continuously extracting, from the thermal decomposition reactor, a liquid phase component which is not collected in a gaseous state at the step of collecting the low-boiling decomposition product, as the high-boiling component.
US Pat. No. 10,968,424

BACILLUS SUBTILIS STRAIN, CULTURE METHOD AND USE THEREOF

SHANDONG BAILONG CHUANGYU...

1. A Bacillus subtilis strain BLCY-005 or a progeny thereof, wherein the strain BLCY-005 was deposited on Oct. 26, 2016 in the China General Microbiological Culture Collection Center, with an accession number of CGMCC No. 13152.
US Pat. No. 10,968,425

GLOBAL GENE REGULATORS (GGR) AS VACCINE CANDIDATES AGAINST PARATUBERCULOSIS

WISCONSIN ALUMNI RESEARCH...

1. A method of detecting subjects that have been vaccinated with a Mycobacterium avium subspecies paratuberculosis vaccine, the method comprising the steps of(a) obtaining a sample from the subject;
(b) isolating cells from the sample;
(c) stimulating the cells with Johnin purified protein derivative (PPDj); and
(d) measuring the anti-PPDj IgG level in the sample and measuring the IFN-? level in the supernatant of the stimulated cell, wherein increased levels of IFN-? and anti-PPDj IgG as compared to levels in a known naïve subject indicate a subject has been vaccinated with Mycobacterium avium subspecies paratuberculosis vaccine.
US Pat. No. 10,968,170

VISCOMETRIC PROPERTIES IMPROVER

KAO CORPORATION, Tokyo (...

1. An additive composition for a liquid coolant, comprisinga compound (A) represented by the following formula (1) and a compound (B) represented by the following formula (2):
R1O?R2O?mSO3M  (1)
R3O—SO3M  (2)
wherein R1 and R3 are the same as or different from each other and each represent a linear or branched alkyl group or alkenyl group having 16 or more and 24 or less carbon atoms; R2 represents an ethylene group or a propylene group; m represents an addition molar number of R2O of 1 or more and 15 or less; and M represents a cation or a hydrogen atom,
a non-freezability additive, an anticorrosion additive, and a rust inhibitor, and
water.
US Pat. No. 10,968,426

UNIVERSAL DONOR STEM CELLS AND RELATED METHODS

President and Fellows of ...

1. An isolated stem cell comprising reduced expression of MHC-I and MHC-II human leukocyte antigens (HLA) relative to a wild-type stem cell of the same cell type and increased expression of a tolerogenic factor relative to a wild-type stem cell of the same cell type,wherein the MHC-I human leukocyte antigens are HLA-A, HLA-B, and HLA-C,
wherein the MHC-II human leukocyte antigens are HLA-DP, HLA-DQ, and HLA-DR, and
wherein the tolerogenic factor is CD47; and
wherein the stem cell is an embryonic stem cell or an induced pluripotent stem cell.
US Pat. No. 10,968,427

METHODS OF EXPANDING EMBRYONIC STEM CELLS IN A SUSPENSION CULTURE

1. A method of expanding and maintaining human pluripotent stem cells in an undifferentiated state, the method comprising culturing the human pluripotent stem cells in a feeder cell-free culture, comprising a defined culture medium which comprises an IL6RIL6 chimera and basic fibroblast growth factor (bFGF) for at least one passage, wherein said medium is devoid of serum, wherein said IL6RIL6 chimera comprises the amino acid sequence set forth by SEQ ID NO: 33, said culture medium is capable of maintaining the human pluripotent stem cells in an undifferentiated state, and wherein said human pluripotent stem cells are capable of differentiating into the endoderm, mesoderm and ectoderm embryonic germ layers, thereby expanding and maintaining human pluripotent stem cells in the undifferentiated state.
US Pat. No. 10,971,249

SYSTEMS AND METHODS FOR OFF-TARGET SEQUENCE DETECTION

ILLUMINA, INC., San Dieg...

1. A computer-implemented method of identifying off-target matches from a set of candidate primer sequences on a genome reference sequence, the method comprising:receiving onto a data storage unit a plurality of candidate primer sequences, wherein some or all of the plurality of candidate primer sequences are organized into clusters, wherein each cluster comprises a respective common region shared by candidate primer sequences within the respective cluster;
populating or updating a cache with one or more respective rule satisfaction calculations for respective common regions when they are initially evaluated as candidate matches or verified matches;
for each candidate primer sequence, calculating using a processor a plurality of candidate matches on the genome reference sequence for the candidate primer sequences, wherein calculating the plurality of candidate matches comprises reusing one or more rule satisfaction calculations for common regions when present in the cache;
calculating, using the processor, verified matches on the genome reference sequence based on the candidate matching locations satisfying a plurality of matching verification rules, wherein calculating the verified matches comprises reusing one or more rule satisfaction calculations for common regions when present in the cache;
performing matching calculations of the verified matches, using the processor, to determine whether the verified matches form an off-target match condition on the genome reference sequence; and
generating a location profile on the genome reference sequence based on the off-target match condition from the verified matches that meet a predetermined off-target threshold.
US Pat. No. 10,968,429

CHELATED IRON-CONTAINING CULTURE MEDIUM FOR NEURAL STEM CELLS

AJINOMOTO CO., INC., Tok...

1. A method of proliferating neural stem cells and/or neural progenitor cells while maintaining an undifferentiated state, comprising culturing said neural stem cells and/or neural progenitor cells in a chemically-defined culture medium which comprises chelated iron, wherein said chelated iron is bound to transferrin and present in said medium in an amount of 3 to 7 ppb.
US Pat. No. 10,968,430

USE OF SPECIFIC REGULATORY T-CELLS TO INDUCE IMMUNE TOLERANCE

THE HENRY M. JACKSON FOUN...

1. A construct comprising a nucleic acid molecule encoding a T cell receptor (TCR) having the amino acid sequence of SEQ ID NO:1.
US Pat. No. 10,968,431

ADOPTIVE TRANSFER OF CD8+ T CELL CLONES DERIVED FROM CENTRAL MEMORY CELLS

City of Hope, Duarte, CA...

1. A method for performing adoptive immunotherapy, comprising administering to a primate subject in need thereof a treatment-effective amount of a cytotoxic T lymphocyte (CTL) preparation, wherein the CTL preparation comprises 60% or more primate CD8+ effector T (TE) cells and one or more of the CD8+ TE cells of the CTL preparation comprise a gene encoding a protein that specifically binds to a cancer cell, and wherein the 60% or more primate CD8+ TE cells have:(a) decreased expression of CD62L as compared to CD8+ central memory T (TCM) cells; and
(b) improved survival and/or expansion for at least 10-days when cultured in vitro in the presence of IL-15 and in the absence of antigen stimulation as compared to when cultured in vitro in the absence of IL-15 and in the absence of antigen stimulation.
US Pat. No. 10,966,381

HAPLOID EMBRYOGENESIS

STICHTING WAGENINGEN RESE...

1. A method of producing a haploid plant embryo comprising culturing or growing haploid plant material in the presence of a hydroxamic acid compound, wherein the hydroxamic acid compound is chosen from trichostatin A, suberoylanilide hydroxamic acid, suberoyl bis-hydroxamic acid, scriptaid, oxamflatin, tubacin, APHA Compound 8, and apicidin.
US Pat. No. 10,968,432

PROTEINS INCREASING PANCREATIC ? CELL NUMBER AND METHODS OF USE

University of Oregon, Eu...

1. A method for identifying a host-associated gut bacteria or protein thereof that increases ? cell number and/or proliferation, comprising:contacting germ-free zebrafish with one or more host-associated bacteria or protein thereof;
measuring a number of ? cells or proliferation of ? cells in the zebrafish; and
comparing the number of ? cells or proliferation of the ? cells with a control, thereby identifying the host-associated bacteria or protein thereof that increases ? cell number and/or proliferation.
US Pat. No. 10,966,382

TOMATO HYBRID DR1398TH AND PARENTS THEREOF

Seminis Vegetable Seeds, ...

1. A tomato plant of tomato hybrid DR1398TH, a sample of seed of said hybrid DR1398TH having been deposited under ATCC Accession Number PTA-122142.
US Pat. No. 10,968,433

METHOD FOR HARVESTING STEM AND PROGENITOR CELLS AND METHOD OF TREATMENT OF KIDNEY DISEASE AND NEUROLOGICAL DISEASE

BOARD OF SUPERVISORS OF L...

1. A method of treating kidney disease in a patient comprising the steps of:isolating podocyte progenitor cells from a urine specimen of the patient;
growing the podocyte progenitor cells in vitro; and
selecting the podocyte progenitor cells that have positive expression for CD133; and
implanting the podocyte progenitor cells into a kidney of the patient.
US Pat. No. 10,966,383

COTTON VARIETY PX2A28W3FE

Phytogen Seed Company, LL...

1. A seed of cotton variety designated PX2A28W3FE, or a part thereof, representative seed of the variety having been deposited under ATCC Accession No. PTA-124859 on Jan. 29, 2018.
US Pat. No. 10,968,434

EXOSOME ACTIVE FORMULATION FOR INHIBITING ENDOTHELIAL CELL MIGRATION, AND PREPARATION METHOD AND APPLICATION

1. A method of preparing an exosome active formulation capable of inhibiting endothelial cell migration comprising:(a) isolating primary umbilical vein endothelial cells
(b) culturing and passaging the primary umbilical vein endothelial cells in a first culture medium, thereby forming a culture comprising subcultured endothelial cells in a first medium;
(c) adding 1.5×10?3-1.5×10?2 ng/mL anisodamine to the first medium to pretreat the subcultured endothelial cells;
(d) 3-5 hours after adding the anisodamime, replacing the first medium with a new endothelial cell culture medium;
(e) adding 5-15 ng/mL TNF-? to the new endothelial cells culture medium;
(f) culturing the cells in the new endothelial cell culture medium with TNF-? for 18-30 hours after adding the TNF-?, thereby forming a culture comprising cultivated endothelial cells in a second medium;
(g) extracting exosomes from the second medium; and
(h) identifying the exosomes.